Egfr - epidermal growth factor receptor Gene
Also Known as Wa5; wa2; Erbb; Errp; wa-2; Errb1; 9030024J15Rik
Species: Mus musculus
About Egfr
This gene has 5 transcripts (splice variants), 283 orthologues, 53 paralogues and is associated with 180 phenotypes. Broad expression in liver adult (RPKM 26.7), liver E18 (RPKM 8.7) and 15 other tissues.
Summary
Enables epidermal growth factor binding activity and epidermal growth factor-activated receptor activity. Involved in cellular response to amino acid stimulus and positive regulation of fibroblast proliferation. Acts upstream of or within several processes, including animal organ development; epidermal growth factor receptor signaling pathway; and protein autophosphorylation. Located in several cellular components, including basolateral plasma membrane; endocytic vesicle; and perinuclear region of cytoplasm. Is expressed in several structures, including alimentary system; brain; integumental system; limb; and respiratory system. Used to study Coronavirus infectious disease and aortic valve disease. Human ortholog(s) of this gene implicated in several diseases, including colorectal cancer; lung non-small cell carcinoma (multiple); pancreatic cancer; prostate cancer; and pulmonary Tuberculosis. Orthologous to human EGFR (epidermal growth factor receptor). [provided by Alliance of Genome Resources, Apr 2022]
Egfr Products (2)
| mRNA | Protein | Name |
|---|---|---|
| NM_207655.2 | NP_997538.1 | epidermal growth factor receptor isoform 1 precursor |
| NM_007912.4 | NP_031938.1 | epidermal growth factor receptor isoform 2 precursor |
Gene Ontology
- Molecular Function
- Biological Process
- Cellular Component
| Cellular Component GO Annotation | Evidence | References | Source |
|---|---|---|---|
| located in basolateral plasma membrane |
IDA
IDA: Inferred from direct assay
|
7723235 | MGI |
| located in cell surface |
IDA
IDA: Inferred from direct assay
|
23918928 | MGI |
| located in endocytic vesicle |
IDA
IDA: Inferred from direct assay
|
10534613 | MGI |
| located in intracellular anatomical structure |
IDA
IDA: Inferred from direct assay
|
10534613 | MGI |
| located in nucleus |
IDA
IDA: Inferred from direct assay
|
20208556 | MGI |
| located in perinuclear region of cytoplasm |
IDA
IDA: Inferred from direct assay
|
20208556 | MGI |
| is active in plasma membrane |
IDA
IDA: Inferred from direct assay
|
6248866 | MGI |
| located in plasma membrane |
IDA
IDA: Inferred from direct assay
|
7641815 | MGI |
| is active in plasma membrane |
IGI
IGI: Inferred from genetic interaction
|
28783046 | MGI |
Egfr Protein Structure
Recep_L_domain: pfam01030 (56 - 167)
Furin-like: pfam00757 (183 - 334)
Recep_L_domain: pfam01030 (361 - 480)
GF_recep_IV: pfam14843 (504 - 635)
TM_ErbB1: cd12093 (633 - 678)
PTKc_EGFR: cd05108 (705 - 1017)
- 0
- 200
- 400
- 600
- 800
- 1000
- 1210 a.a.
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
epidermal growth factor receptor |
|
Recombinant Egfr Proteins
| Cat. No. | Product Name | Accession | Purity |
|---|---|---|---|
| HY-P72988 | EGFR Protein, Mouse (HEK293, Fc) | Q01279 (L25-S647) | ≥ 95%, as determined by reducing SDS-PAGE. |
| HY-P72989 | EGFR Protein, Mouse (HEK293, His, solution) | Q01279 (L25-S647) | ≥ 95%, as determined by reducing SDS-PAGE. |
Related Agents
- Approval
- Clinical Phase
- Pre-clinical Phase
Approval
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-15772 | Osimertinib | Inhibitor | 99.96% | Yes |
| HY-P9907 | Trastuzumab | Inhibitor | 99.80% | Unkown |
| HY-P9905 | Cetuximab | Inhibitor | 99.81% | Unkown |
| HY-50895 | Gefitinib | Inhibitor | 99.99% | Yes |
| HY-138298A | Trastuzumab deruxtecan | Inhibitor | 99.89% | Unkown |
| HY-50896 | Erlotinib | Inhibitor | 99.99% | Yes |
| HY-10261 | Afatinib | Inhibitor | 99.92% | Yes |
| HY-138298 | Trastuzumab deruxtecan (solution) | Inhibitor | 99.40% | Unkown |
| HY-50898 | Lapatinib | Inhibitor | 99.83% | Yes |
| HY-16069 | Tucatinib | Inhibitor | 99.82% | Yes |
| HY-P9921 | Trastuzumab emtansine | Inhibitor | 99.74% | Unkown |
| HY-32721 | Neratinib | Inhibitor | 99.94% | Yes |
| HY-P9985 | Disitamab vedotin | Inhibitor | 99.06% | Unkown |
| HY-13272 | Dacomitinib | Inhibitor | 99.74% | Yes |
| HY-15772A | Osimertinib mesylate | Inhibitor | 99.97% | Yes |
| HY-109061 | Lazertinib | Inhibitor | 99.87% | Unkown |
| HY-P9921A | Trastuzumab emtansine (solution) | 98.27% | Unkown | |
| HY-12008 | Erlotinib Hydrochloride | Inhibitor | 99.94% | Yes |
| HY-10261A | Afatinib dimaleate | Inhibitor | 99.74% | Yes |
| HY-112870 | Firmonertinib | Inhibitor | 99.89% | Unkown |
| HY-112823 | Almonertinib | Inhibitor | 99.83% | Unkown |
| HY-104065 | Pyrotinib | Inhibitor | 99.89% | Unkown |
| HY-50895A | Gefitinib hydrochloride | Inhibitor | 99.85% | Yes |
| HY-132842 | Sunvozertinib | Inhibitor | 99.62% | Unkown |
| HY-N0281 | Daphnetin | Inhibitor | 99.77% | Unkown |
| HY-135815 | Mobocertinib | Inhibitor | 99.60% | Yes |
| HY-15164A | Icotinib | Inhibitor | 99.96% | Yes |
| HY-79077 | Osimertinib dimesylate | Inhibitor | 99.96% | Yes |
| HY-32721B | Neratinib maleate | Inhibitor | 99.74% | Yes |
| HY-164718 | Sevabertinib | Inhibitor | 99.90% | Unkown |
| HY-50898A | Lapatinib ditosylate | Inhibitor | 99.96% | Yes |
| HY-19730 | Olmutinib | Inhibitor | 99.88% | Unkown |
| HY-112870A | Firmonertinib mesylate | Inhibitor | 99.97% | Unkown |
| HY-15772R | Osimertinib (Standard) | Inhibitor | 99.69% | Unkown |
| HY-50898B | Lapatinib ditosylate monohydrate | Inhibitor | 99.99% | Yes |
| HY-104065B | Pyrotinib dimaleate | Inhibitor | 98.04% | Unkown |
| HY-112823B | Almonertinib hydrochloride | Inhibitor | 98.92% | Unkown |
| HY-112823A | Almonertinib mesylate | Inhibitor | 99.67% | Unkown |
| HY-135815A | Mobocertinib succinate | Inhibitor | 99.83% | Yes |
| HY-50896R | Erlotinib (Standard) | Inhibitor | 99.97% | Unkown |
| HY-16069A | Tucatinib hemiethanolate | Inhibitor | 98.82% | Yes |
| HY-15164 | Icotinib Hydrochloride | Inhibitor | 99.89% | Yes |
| HY-50895R | Gefitinib (Standard) | Inhibitor | 99.94% | Unkown |
| HY-118263 | Dacomitinib hydrate | Inhibitor | 99.54% | Unkown |
| HY-12008R | Erlotinib Hydrochloride (Standard) | Inhibitor | 99.73% | Unkown |
| HY-10261D | Afatinib oxalate | Inhibitor | / | Unkown |
| HY-50898C | Lapatinib tosylate | Inhibitor | / | Unkown |
| HY-135815B | Mobocertinib mesylate | Inhibitor | / | Unkown |
| HY-50895B | Gefitinib dihydrochloride | Inhibitor | / | Unkown |
| HY-101820A | Simotinib hydrochloride | Inhibitor | / | Unkown |
| HY-12008A | Erlotinib mesylate | Inhibitor | / | Unkown |
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-P9977 | Amivantamab | Inhibitor | 99.90% | Unkown |
| HY-P9912 | Pertuzumab | Inhibitor | 99.80% | Unkown |
| HY-P99041 | Panitumumab | Inhibitor | 99.77% | Unkown |
| HY-P99380 | Zanidatamab | Inhibitor | 98.56% | Unkown |
| HY-P99507 | Zenocutuzumab | Inhibitor | 99.9% | Unkown |
| HY-P9968 | Nimotuzumab | Inhibitor | 96.80% | Unkown |
| HY-P9964 | Necitumumab | Inhibitor | 99.82% | Unkown |
| HY-P99030 | Margetuximab | Inhibitor | ≥99.0% | Unkown |
Clinical Phase
| Cat. No. | Product Name |
Effect
|
Purity |
Phase |
|---|---|---|---|---|
| HY-14596 | Genistein | Inhibitor | 99.82% | Phase 4 |
| HY-137433 | Befotertinib | Inhibitor | 99.77% | Phase 4 |
| HY-131686 | Ganglioside GT1b (bovine) ammonium | Activator | 98.0% | Phase 4 |
| HY-50895G | Gefitinib (GMP) | Inhibitor | / | Phase 4 |
| HY-P99813 | Patritumab deruxtecan | 99.08% | Phase 3 | |
| HY-164702 | BL-B01D1 | Inhibitor | 98.40% | Phase 3 |
| HY-18750 | Zorifertinib | Inhibitor | 99.37% | Phase 3 |
| HY-171265 | Becotatug vedotin | Inhibitor | 96.99% | Phase 3 |
| HY-15729 | Rociletinib | Inhibitor | 99.67% | Phase 3 |
| HY-15730 | Poziotinib | Inhibitor | 99.96% | Phase 3 |
| HY-132259 | Depatuxizumab mafodotin | 99.65% | Phase 3 | |
| HY-12872 | Nazartinib | Inhibitor | 99.53% | Phase 3 |
| HY-164762 | Trastuzumab rezetecan | Inhibitor | 98.01% | Phase 3 |
| HY-112299 | Zipalertinib | Inhibitor | 99.62% | Phase 3 |
| HY-139920 | Oritinib | Inhibitor | 99.59% | Phase 3 |
| HY-19803 | Naquotinib mesylate | Inhibitor | 98.06% | Phase 3 |
| HY-19816A | Avitinib maleate | Inhibitor | 99.86% | Phase 3 |
| HY-13314 | Tesevatinib | Inhibitor | 99.41% | Phase 3 |
| HY-120590 | Ruserontinib | Inhibitor | 99.32% | Phase 3 |
| HY-P990697 | Anvatabart | Inhibitor | 98.15% | Phase 3 |
| HY-138751A | limertinib diTFA | Inhibitor | 98.96% | Phase 3 |
| HY-118998 | TX2-121-1 | Degrader | / | Phase 3 |
| HY-10530A | Varlitinib tosylate | Inhibitor | / | Phase 3 |
| HY-109189A | Rezivertinib hydrochloride | Inhibitor | / | Phase 3 |
| HY-N14349 | Asterriquinone | Inhibitor | / | Phase 3 |
| HY-106204 | Nelipepimut-S | / | Phase 3 | |
| HY-172820 | Trastuzumab envedotin | Inhibitor | / | Phase 3 |
| HY-13050 | Sapitinib | Inhibitor | 99.93% | Phase 2 |
| HY-10367 | Canertinib | Inhibitor | 99.74% | Phase 2 |
| HY-32718 | Pelitinib | Inhibitor | 99.13% | Phase 2 |
| HY-153268 | Silevertinib | Inhibitor | 99.74% | Phase 2 |
| HY-10045 | AEE788 | Inhibitor | 98.39% | Phase 2 |
| HY-14674 | CP-724714 | Inhibitor | 98.72% | Phase 2 |
| HY-10333 | BMS-690514 | Inhibitor | 99.68% | Phase 2 |
| HY-19985 | PF-06459988 | Inhibitor | 99.10% | Phase 2 |
| HY-12972 | Mavelertinib | Inhibitor | 99.34% | Phase 2 |
| HY-172429A | Enozertinib hemihydrate | Inhibitor | 99.98% | Phase 2 |
| HY-17632 | Tarloxotinib bromide | Inhibitor | 98.75% | Phase 2 |
| HY-19815 | Olafertinib | Inhibitor | 99.51% | Phase 2 |
| HY-10251 | BMS-599626 | Inhibitor | 98.56% | Phase 2 |
| HY-107367A | Epertinib hydrochloride | Inhibitor | 98.15% | Phase 2 |
| HY-155537 | Pruvonertinib | Inhibitor | 99.50% | Phase 2 |
| HY-19909 | NRC-2694 | Antagonist | 99.84% | Phase 2 |
| HY-153974 | BBT-176 | Inhibitor | 98.98% | Phase 2 |
| HY-W423595 | BEBT-109 | Inhibitor | 98.72% | Phase 2 |
| HY-107367 | Epertinib | Inhibitor | ≥98.0% | Phase 2 |
| HY-P991092 | IBI-334 | Inhibitor | 98.18% | Phase 2 |
| HY-177414 | BB-1701 | Inhibitor | 98.81% | Phase 2 |
| HY-101756 | SDZ281-977 | 98.00% | Phase 2 | |
| HY-164387A | Sutetinib maleate | Inhibitor | / | Phase 2 |
| HY-10223 | CUDC-101 | Inhibitor | 99.05% | Phase 1 |
| HY-13501 | Mubritinib | Inhibitor | 99.91% | Phase 1 |
| HY-164202 | ORM-5029 | Inhibitor | 96.53% | Phase 1 |
| HY-18957 | Lifirafenib | Inhibitor | 98.01% | Phase 1 |
| HY-144680 | BLU-945 | Inhibitor | 99.61% | Phase 1 |
| HY-14346 | PD153035 | Inhibitor | 98.56% | Phase 1 |
| HY-171124 | Tilatamig samrotecan | Inhibitor | 95.26% | Phase 1 |
| HY-136789 | Tuxobertinib | Inhibitor | 99.88% | Phase 1 |
| HY-15196 | TAK-285 | Inhibitor | 98.99% | Phase 1 |
| HY-103443 | HKI-357 | Inhibitor | 99.24% | Phase 1 |
| HY-B0794 | AZ7550 | Inhibitor | 97.09% | Phase 1 |
| HY-116437 | Selatinib | Inhibitor | 98.56% | Phase 1 |
| HY-155079 | DZD1516 | Inhibitor | 99.62% | Phase 1 |
| HY-101820 | Simotinib | Inhibitor | 99.39% | Phase 1 |
| HY-10346 | AV-412 | Inhibitor | 99.17% | Phase 1 |
| HY-153110 | Larotinib | Inhibitor | 99.50% | Phase 1 |
| HY-139300 | Epitinib | Inhibitor | 99.95% | Phase 1 |
| HY-164694 | Emupertinib | Inhibitor | 99.10% | Phase 1 |
| HY-171747 | AMT-562 | Antagonist | 98.65% | Phase 1 |
| HY-177895 | IAM1363 | Inhibitor | 99.40% | Phase 1 |
| HY-111553 | TAS0728 | Inhibitor | 99.71% | Phase 1 |
| HY-128778 | Gozanertinib | Inhibitor | 98.37% | Phase 1 |
| HY-164307 | Pebezertinib | Inhibitor | 99.56% | Phase 1 |
| HY-164464 | BPI-15086 | Inhibitor | / | Phase 1 |
| HY-15732 | BGB-102 | Inhibitor | 99.52% | Phase 1 |
| HY-104066A | Theliatinib tartrate | / | Phase 1 | |
| HY-181954 | ZW-49 | Inhibitor | / | Phase 1 |
| HY-153856 | TAS2940 | Inhibitor | / | Phase 1 |
| HY-177710 | MEDI4276 | / | Phase 1 | |
| HY-110039 | BIBX 1382 dihydrochloride | Inhibitor | / | Phase 1 |
| HY-110333 | BMS-599626 dihydrochloride | Inhibitor | / | Phase 1 |
| Cat. No. | Product Name |
Effect
|
Purity |
Phase |
|---|---|---|---|---|
| HY-P99041A | Panitumumab (anti-EGFR) | Inhibitor | 99.02% | Phase 4 |
| HY-P99969 | Inetetamab | Inhibitor | 96.54% | Phase 4 |
| HY-P99854A | Disitamab (powder) | Inhibitor | 98.44% | Phase 4 |
| HY-P99041B | Panitumumab (powder) | Inhibitor | / | Phase 4 |
| HY-P99275 | Patritumab | Inhibitor | 99.28% | Phase 3 |
| HY-P99406 | Petosemtamab | Degrader | 99.90% | Phase 3 |
| HY-P99676 | Izalontamab | Inhibitor | 99.89% | Phase 3 |
| HY-P99849 | Depatuxizumab | Inhibitor | 99.58% | Phase 3 |
| HY-P99155 | Zalutumumab | 98.34% | Phase 3 | |
| HY-P990049 | Becotatug | Inhibitor | 99.00% | Phase 3 |
| HY-P99437 | Anbenitamab | Inhibitor | 99.22% | Phase 3 |
| HY-P99455 | Bafisontamab | Inhibitor | 99.9% | Phase 3 |
| HY-P99630 | Gancotamab antibody | Inhibitor | ≥99.0% | Phase 3 |
| HY-P99831 | Coprelotamab | / | Phase 3 | |
| HY-P991588 | HLX-22 | Antagonist | 99.47% | Phase 3 |
| HY-P991508 | Sym004 | Inhibitor | 98.97% | Phase 3 |
| HY-P99155A | Zalutumumab (powder) | Inhibitor | / | Phase 3 |
| HY-P99268 | Seribantumab | Inhibitor | 96.043% | Phase 2 |
| HY-P9969 | Matuzumab | 99.50% | Phase 2 | |
| HY-P99936 | Elgemtumab | Inhibitor | 99.00% | Phase 2 |
| HY-P99778 | Ontuxizumab | 99.85% | Phase 2 | |
| HY-P990314 | AFM24 | Inhibitor | 96.26% | Phase 2 |
| HY-P99295 | Imgatuzumab | Inhibitor | 99.41% | Phase 2 |
| HY-P990071 | Fepixnebart | Inhibitor | 96.46% | Phase 2 |
| HY-P99605 | Cinrebafusp alfa | Inhibitor | 98.53% | Phase 2 |
| HY-P99306 | Modotuximab | Inhibitor | 99.08% | Phase 2 |
| HY-P99628 | Futuximab | Inhibitor | 98.09% | Phase 2 |
| HY-P991237 | Nezutatug | Inhibitor | 99.9% | Phase 2 |
| HY-P991571 | GC1118 | 99.22% | Phase 2 | |
| HY-P990913 | Dalmitamig | 97.158% | Phase 2 | |
| HY-P99672 | Istiratumab | Inhibitor | 98.45% | Phase 2 |
| HY-P991238 | MEDI4276 Antibody | Inhibitor | 96.5212% | Phase 2 |
| HY-P9994 | Pertuzumab zuvotolimod | Inhibitor | 98.64% | Phase 2 |
| HY-P991507 | SCT200 | Inhibitor | 99.09% | Phase 2 |
| HY-P991240 | CDX-3379 | Inhibitor | 99.38% | Phase 2 |
| HY-P991524 | MM-111 | Inhibitor | / | Phase 2 |
| HY-P99500 | Cetuximab sarotalocan | Inhibitor | / | Phase 2 |
| HY-P991572 | MM-151 | Antagonist | / | Phase 2 |
| HY-P991233 | BAT1006 | Inhibitor | / | Phase 2 |
| HY-P99896 | Runimotamab | 99.00% | Phase 1 | |
| HY-P99386 | Vesencumab | Inhibitor | 99.34% | Phase 1 |
| HY-P99304 | Lumretuzumab | Inhibitor | ≥99.0% | Phase 1 |
| HY-P99685 | Laprituximab emtansine | Inhibitor | 97.66% | Phase 1 |
| HY-P991235 | FS102 | Degrader | / | Phase 1 |
| HY-P991244 | REGN-1400 | Inhibitor | / | Phase 1 |
| HY-P990609 | KHK-2866 | 98.23% | Phase 1 | |
| HY-P991984 | SIBP-03 | Inhibitor | / | Phase 1 |
Pre-clinical Phase
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-12000 | AG490 | Inhibitor | 99.86% | Unkown |
| HY-P0221 | PACAP (1-38), human, ovine, rat | Inducer | 99.99% | Unkown |
| HY-13524 | AG-1478 | Inhibitor | 99.57% | Unkown |
| HY-P10408 | Candidalysin | Activator | 99.81% | Unkown |
| HY-101084 | NSC 228155 | Activator | 99.58% | Unkown |
| HY-164992 | Trastuzumab vedotin | Inhibitor | 98.05% | Unkown |
| HY-13595 | Chrysophanol | Inhibitor | 99.73% | Unkown |
| HY-N0280 | Corosolic acid | 99.95% | Unkown | |
| HY-16558 | Butein | Inhibitor | 99.64% | Unkown |
| HY-N2409 | Delphinidin chloride | Inhibitor | 98.0% | Unkown |
| HY-171135 | Cetuximab MMAE | Inhibitor | 99.64% | Unkown |
| HY-100848 | TX1-85-1 | Inhibitor | 99.65% | Unkown |
| HY-12461 | WS6 | Activator | 99.30% | Unkown |
| HY-100958 | 4-DAMP | Inhibitor | 99.96% | Unkown |
| HY-B0793 | AZ-5104 | Inhibitor | 99.91% | Unkown |
| HY-156698 | HJM-561 | Degrader | 99.52% | Unkown |
| HY-N7922 | Urolithin M5 | 97.31% | Unkown | |
| HY-100742 | GNE-140 racemate | Inhibitor | 99.25% | Unkown |
| HY-19816 | Avitinib | Inhibitor | 99.95% | Unkown |
| HY-123921 | Gefitinib-based PROTAC 3 | Degrader | 99.98% | Unkown |
| HY-15644 | Tyrphostin 23 | Inhibitor | 98.19% | Unkown |
| HY-14596R | Genistein (Standard) | Inhibitor | 98.70% | Unkown |
| HY-168438 | ERBB agonist-1 | Agonist | 99.16% | Unkown |
| HY-108052 | Delphinidin 3-glucoside chloride | Inhibitor | 99.89% | Unkown |
| HY-N0447 | 8-Gingerol | Inhibitor | 99.82% | Unkown |
| HY-162713 | MTX-531 | Inhibitor | 99.87% | Unkown |
| HY-120852 | JG26 | Inhibitor | 98.14% | Unkown |
| HY-112411 | PD 174265 | Inhibitor | 98.35% | Unkown |
| HY-W016412 | Coenzyme Q0 | Inhibitor | 99.79% | Unkown |
| HY-129550 | BI-4020 | Inhibitor | 99.30% | Unkown |
| HY-13896 | PD168393 | Inhibitor | 98.01% | Unkown |
| HY-41404 | Piperonylic acid | 99.94% | Unkown | |
| HY-109189 | Rezivertinib | Inhibitor | 99.62% | Unkown |
| HY-100434 | PD-161570 | Inhibitor | 98.78% | Unkown |
| HY-48999A | FSK hydrochloride | 99.97% | Unkown | |
| HY-131864 | SJF-1528 | Degrader | 98.90% | Unkown |
| HY-141640 | MS154 | Inhibitor | 99.71% | Unkown |
| HY-138751 | limertinib | Inhibitor | 99.15% | Unkown |
| HY-N0211 | Cyasterone | Inhibitor | 99.58% | Unkown |
| HY-N2450 | Sulforaphene | Inhibitor | 99.78% | Unkown |
| HY-18609 | PD158780 | Inhibitor | 99.47% | Unkown |
| HY-155736 | MAPK-IN-2 | Inhibitor | 99.66% | Unkown |
| HY-W782083 | p-SCN-Bn-NOTA trihydrochloride | 99.75% | Unkown | |
| HY-125168 | EGA | Modulator | 99.76% | Unkown |
| HY-14596S | Genistein-d4 | Inhibitor | 98.81% | Unkown |
| HY-N2184 | Furanodienone | 99.90% | Unkown | |
| HY-10530 | Varlitinib | Inhibitor | 99.92% | Yes |
| HY-141676 | HyT36 | Degrader | 96.0% | Unkown |
| HY-N7005 | Clitorin | Inhibitor | 99.45% | Unkown |
| HY-15375 | Allitinib | Inhibitor | 98.88% | Unkown |
| HY-100213 | EAI045 | Inhibitor | 99.06% | Unkown |
| HY-10322 | Falnidamol | Inhibitor | 99.41% | Unkown |
| HY-N0891 | Tubeimoside II | Inhibitor | 99.90% | Unkown |
| HY-138916 | PF-06672131 | Inhibitor | 99.47% | Unkown |
| HY-10367A | Canertinib dihydrochloride | Inhibitor | 99.68% | Unkown |
| HY-157229 | STX-721 | Inhibitor | 98.43% | Unkown |
| HY-115605 | CN009543V | Agonist | 99.37% | Unkown |
| HY-20878 | Tyrphostin AG 879 | Inhibitor | 99.26% | Unkown |
| HY-156712 | Depatuxizumab MMAE | Inhibitor | 99.73% | Unkown |
| HY-N9330 | Broussoflavonol F | Inhibitor | 98.11% | Unkown |
| HY-18963 | Lavendustin A | Inhibitor | 98.95% | Unkown |
| HY-B0794B | AZ7550 Mesylate | Inhibitor | 98.70% | Unkown |
| HY-10261B | (E/Z)-Afatinib | Inhibitor | 99.98% | Unkown |
| HY-131865 | SJF-1521 | Degrader | 99.65% | Unkown |
| HY-124813 | PDZ1i | Inhibitor | 99.29% | Unkown |
| HY-123578 | NSC689857 | Inhibitor | 99.49% | Unkown |
| HY-161536 | PROTAC EGFR degrader 9 | Inhibitor | 98.35% | Unkown |
| HY-N2524 | Camelliaside A | Ligand | 99.65% | Unkown |
| HY-N2510 | Myristicin | Inhibitor | 99.89% | Unkown |
| HY-104066 | Theliatinib | Inhibitor | 99.72% | Unkown |
| HY-109061B | Lazertinib mesylate | Inhibitor | 99.85% | Unkown |
| HY-157581 | MS39 | Degrader | 99.89% | Unkown |
| HY-108016 | Peruvoside | Inhibitor | 99.32% | Unkown |
| HY-10325 | CL-387785 | Inhibitor | 99.31% | Unkown |
| HY-108484 | PP 3 | Inhibitor | 99.20% | Unkown |
| HY-134877 | BAY 2476568 | Inhibitor | 99.88% | Unkown |
| HY-12026 | WZ4002 | Inhibitor | 98.99% | Unkown |
| HY-112097 | E260 | Inhibitor | 99.92% | Unkown |
| HY-13464 | ALK-IN-1 | Inhibitor | 99.42% | Unkown |
| HY-137191 | CH7233163 | Inhibitor | 99.41% | Unkown |
| HY-150611 | EGFR-IN-70 | Inhibitor | 98.12% | Unkown |
| HY-115481 | EphB1-IN-1 | Inhibitor | 99.51% | Unkown |
| HY-N2445 | Flavokawain C | Inhibitor | 99.79% | Unkown |
| HY-147858 | PROTAC EGFR degrader 7 | Degrader | 99.48% | Unkown |
| HY-19729 | Naquotinib | Inhibitor | 98.10% | Unkown |
| HY-107364 | MTX-211 | Inhibitor | 99.81% | Unkown |
| HY-172429 | Enozertinib | Inhibitor | 98.86% | Unkown |
| HY-147219A | SIAIS164018 hydrochloride | Degrader | 98.06% | Unkown |
| HY-156640 | Rocbrutinib | Inhibitor | 99.76% | Unkown |
| HY-103442 | CGP52411 | Inhibitor | 99.82% | Unkown |
| HY-N4201 | β-Hydroxyisovalerylshikonin | Inhibitor | 99.83% | Unkown |
| HY-15772S | Osimertinib-d6 | Inhibitor | 99.70% | Unkown |
| HY-128862 | EGFR-IN-7 | Inhibitor | 99.76% | Unkown |
| HY-128576 | DS21360717 | 99.80% | Unkown | |
| HY-12013 | PD153035 Hydrochloride | Inhibitor | 99.48% | Unkown |
| HY-W018800 | 4(3H)-Quinazolinone | Inhibitor | 99.89% | Unkown |
| HY-162299 | EGFR kinase inhibitor 3 | Inhibitor | 99.03% | Unkown |
| HY-17499 | EGFR-IN-12 | Inhibitor | 99.60% | Unkown |
| HY-B1394 | Khellin | Inhibitor | 99.66% | Unkown |
| HY-15844 | AG-825 | Inhibitor | 98.13% | Unkown |
| HY-13895 | WHI-P154 | Inhibitor | 98.77% | Unkown |
| HY-163094 | EGFR-IN-95 | Inhibitor | 98.76% | Unkown |
| HY-13897 | CNX-2006 | Inhibitor | 98.00% | Unkown |
| HY-12001 | WZ-3146 | Inhibitor | 99.28% | Unkown |
| HY-161275 | BI-4732 | Inhibitor | 98.81% | Unkown |
| HY-130616 | EGFR-IN-11 | Inhibitor | 98.76% | Unkown |
| HY-147183B | JBJ-09-063 hydrochloride | Inhibitor | 99.37% | Unkown |
| HY-111415 | EGFR-IN-5 | Inhibitor | 99.49% | Unkown |
| HY-147941A | MS9427 TFA | Degrader | 98.38% | Unkown |
| HY-12010 | BMS-599626 Hydrochloride | Inhibitor | 98.90% | Unkown |
| HY-161408 | GePhos1 | 98.88% | Unkown | |
| HY-153796 | PROTAC Her3 Degrader-8 | Degrader | 99.60% | Unkown |
| HY-172470 | DSPE-PEG2000-GE11 | 95.29% | Unkown | |
| HY-144304 | PROTAC EGFR degrader 2 | Inhibitor | 95.09% | Unkown |
| HY-18603 | FIIN-3 | Inhibitor | 99.01% | Unkown |
| HY-13427 | Allitinib tosylate | Inhibitor | 99.54% | Unkown |
| HY-139617 | Sec61-IN-3 | Inhibitor | 99.22% | Unkown |
| HY-147942 | MS9449 | Degrader | 98.95% | Unkown |
| HY-136430 | JCN037 | Inhibitor | 99.09% | Unkown |
| HY-43533 | Tarlox-TKI | Inhibitor | 98.79% | Unkown |
| HY-161537 | EGFR ligand-9 | Inhibitor | 98.80% | Unkown |
| HY-153901 | PROTAC EGFR degrader 8 | Degrader | 98.90% | Unkown |
| HY-P2503 | EGFR Protein Tyrosine Kinase Substrate | 99.46% | Unkown | |
| HY-110406 | 13(S)-HPODE | Activator | 95.05% | Unkown |
| HY-N1988 | Cucurbitacin IIa | Inhibitor | 99.90% | Unkown |
| HY-149530 | EGFR-IN-86 | Inhibitor | 99.92% | Unkown |
| HY-P5314 | OK2 | Inhibitor | 99.13% | Unkown |
| HY-N1073 | Wighteone | Inhibitor | 98.71% | Unkown |
| HY-117155 | PKI-166 | Inhibitor | 98.92% | Unkown |
| HY-146349 | PROTAC EGFR degrader 4 | Degrader | 99.70% | Unkown |
| HY-175252 | PROTAC EGFR degrader 14 | Degrader | 99.26% | Unkown |
| HY-101960A | Tyrphostin A51 | Inhibitor | 99.0% | Unkown |
| HY-P4082 | ErbB-2-binding peptide-1 | Ligand | 99.52% | Unkown |
| HY-161633 | PROTAC EGFR degrader 11 | Degrader | 99.20% | Unkown |
| HY-163428 | Perzebertinib | Inhibitor | / | Unkown |
| HY-12029 | WZ8040 | Inhibitor | 98.29% | Unkown |
| HY-147183A | JBJ-09-063 TFA | Inhibitor | 99.64% | Unkown |
| HY-150023 | BI-1622 | Inhibitor | 98.02% | Unkown |
| HY-138627A | AST5902 trimesylate | Inhibitor | 98.75% | Unkown |
| HY-W013857 | Lavendustin C | Inhibitor | 98.17% | Unkown |
| HY-112293 | GW2974 | 99.16% | Unkown | |
| HY-177008 | PROTAC HER2 degrader-1 | Degrader | 98.0% | Unkown |
| HY-P11308 | Cys-GE11 | 98.03% | Unkown | |
| HY-123952 | RTC-5 | Inhibitor | 99.37% | Unkown |
| HY-101429 | RG13022 | Inhibitor | 96.74% | Unkown |
| HY-79511 | FAAH-IN-2 | Ligand | 99.12% | Unkown |
| HY-RS04209 | EGFR Human Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-175839 | PROTAC EGFR degrader 15 | Degrader | 99.23% | Unkown |
| HY-124674A | CCT365623 hydrochloride | Inhibitor | 98.07% | Unkown |
| HY-103566 | LY456236 | Inhibitor | 99.57% | Unkown |
| HY-123035 | Gamendazole | Inhibitor | 99.44% | Unkown |
| HY-15336 | AG 555 | Inhibitor | 98.0% | Unkown |
| HY-157579 | MS154N | 99.30% | Unkown | |
| HY-P1828A | EGFRvIII peptide (PEPvIII) TFA | 98.73% | Unkown | |
| HY-P10792 | HER2-targeted peptide H6F | 98.85% | Unkown | |
| HY-101219 | VEGFR-IN-1 | Inhibitor | 99.07% | Unkown |
| HY-161126 | EGFR-IN-98 | Inhibitor | 99.12% | Unkown |
| HY-103440 | EGFR/ErbB-2/ErbB-4 inhibitor-3 | Inhibitor | 96.78% | Unkown |
| HY-19985A | (3S,4S)-PF-06459988 | 98.97% | Unkown | |
| HY-101041 | (E)-AG 556 | Inhibitor | 99.91% | Unkown |
| HY-164919 | Calotatug ginistinag | Inhibitor | 95.94% | Unkown |
| HY-126320 | EGFR-IN-8 | Inhibitor | 98.01% | Unkown |
| HY-15769 | WHI-P180 | Inhibitor | 99.84% | Unkown |
| HY-100214 | EAI001 | Inhibitor | 99.93% | Unkown |
| HY-142283AS | Dosimertinib-d5 mesylate | Inhibitor | 99.50% | Unkown |
| HY-150024 | BI-4142 | Inhibitor | 98.02% | Unkown |
| HY-111138 | CZC-8004 | Inhibitor | 99.81% | Unkown |
| HY-112474 | Tyrphostin AG 112 | Inhibitor | 98.31% | Unkown |
| HY-135805B | (Rac)-JBJ-04-125-02 acetate | / | Unkown | |
| HY-131864A | SJF-1528 hemihydrate | Degrader | 98.90% | Unkown |
| HY-112420 | EGFR/ErbB-2-IN-2 | Inhibitor | 99.45% | Unkown |
| HY-P10224A | G7-18NATE TFA | 98.06% | Unkown | |
| HY-12806 | AG1557 | Inhibitor | 99.54% | Unkown |
| HY-142512 | EGFR-IN-24 | Inhibitor | 98.71% | Unkown |
| HY-101450 | PF-6274484 | Inhibitor | 98.76% | Unkown |
| HY-13984 | NT-1 | Inhibitor | 99.40% | Unkown |
| HY-N6577 | Astragaloside VI | 99.95% | Unkown | |
| HY-N7424 | 4,7-Dihydroxycoumarin | Inhibitor | 98.25% | Unkown |
| HY-172920 | Wnt/β-catenin-IN-6 | Inhibitor | 98.34% | Unkown |
| HY-118532 | Tyrphostin AG30 | Inhibitor | 98.51% | Unkown |
| HY-157480 | EGFR/AURKB-IN-1 | Inhibitor | 99.43% | Unkown |
| HY-15729A | Rociletinib hydrobromide | Inhibitor | 98.04% | Yes |
| HY-107459 | (E/Z)-AG490 | Inhibitor | 99.71% | Unkown |
| HY-156284 | EGFR-IN-89 | Inhibitor | 98.75% | Unkown |
| HY-N6932 | Voacamine | 99.64% | Unkown | |
| HY-101042 | AG-494 | Inhibitor | 98.69% | Unkown |
| HY-119944 | JND3229 | Inhibitor | 99.38% | Unkown |
| HY-153110A | Larotinib mesylate hydrate | Inhibitor | 98.66% | Unkown |
| HY-141481 | DP-C-4 | Inhibitor | 98.15% | Unkown |
| HY-156741A | EGFR-IN-87 hydrochloride | Inhibitor | 98.0% | Unkown |
| HY-112345 | PD-089828 | Inhibitor | 98.07% | Unkown |
| HY-164763 | SHR-A1201 | Inhibitor | 97.35% | Unkown |
| HY-RS04472 | ERBB4 Human Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-101522 | CHMFL-EGFR-202 | Inhibitor | 99.75% | Unkown |
| HY-179572 | STA-013 | Inhibitor | 99.18% | Unkown |
| HY-P11078A | LARLLT TFA | 99.89% | Unkown | |
| HY-161781 | HVH-2930 | Inhibitor | 96.54% | Unkown |
| HY-145960A | MC-Val-Cit-PAB-Amide-TLR7 agonist 4 formic | Agonist | 97.70% | Unkown |
| HY-100923 | H-9 Dihydrochloride | Inhibitor | 98.98% | Unkown |
| HY-50896S | Erlotinib-d6 | Inhibitor | 99.84% | Unkown |
| HY-139997 | DDC-01-163 | Degrader | 99.05% | Unkown |
| HY-N1166 | Tephrosin | 98.02% | Unkown | |
| HY-103441 | JNJ28871063 hydrochloride | Inhibitor | 98.36% | Unkown |
| HY-158149 | T-1-PMPA | Inhibitor | 99.70% | Unkown |
| HY-133780 | Afatinib impurity 11 | Inhibitor | 99.10% | Unkown |
| HY-P1855 | HER2/neu (654-662) GP2 | 98.26% | Unkown | |
| HY-170820 | XYD049 | Inhibitor | 99.46% | Unkown |
| HY-172414 | Andamertinib | Inhibitor | 99.06% | Unkown |
| HY-101426 | RG14620 | Inhibitor | 99.02% | Unkown |
| HY-143337 | EGFR-IN-47 | Inhibitor | 96.01% | Unkown |
| HY-149889 | EGFR-IN-78 | Inhibitor | 99.57% | Unkown |
| HY-131686A | Ganglioside GT1b (porcine) ammonium | Activator | 98% | Unkown |
| HY-RS04466 | ERBB2 Human Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-100064 | O-Desmethyl gefitinib | Inhibitor | 99.40% | Unkown |
| HY-101006 | Methyl 2,5-dihydroxycinnamate | Inhibitor | 99.77% | Unkown |
| HY-50898S | Lapatinib-d4 | Inhibitor | 99.02% | Unkown |
| HY-151159 | DHFR-IN-4 | Inhibitor | 99.19% | Unkown |
| HY-162890 | EGFR-IN-122 | Inhibitor | 99.98% | Unkown |
| HY-15801 | HG-14-10-04 | Inhibitor | 98.53% | Unkown |
| HY-161927 | EGFR-TK-IN-4 | Inhibitor | 99.90% | Unkown |
| HY-156872 | MTX-216 | Inhibitor | / | Unkown |
| HY-157582 | MS39N | Control | 98.0% | Unkown |
| HY-50895S2 | Gefitinib-d3 | Inhibitor | 98.39% | Unkown |
| HY-113599 | Isoprocurcumenol | Activator | 95.41% | Unkown |
| HY-13450 | ZM 449829 | Inhibitor | 99.73% | Unkown |
| HY-112870AS | Firmonertinib-d3 mesylate | 99.00% | Unkown | |
| HY-50895S | Gefitinib-d8 | Inhibitor | 98.42% | Unkown |
| HY-135805A | (Rac)-JBJ-04-125-02 | Inhibitor | / | Unkown |
| HY-19617A | EGFR-IN-1 hydrochloride | Inhibitor | / | Unkown |
| HY-100962 | (E)-AG 99 | Inhibitor | 98.12% | Unkown |
| HY-19617 | EGFR-IN-1 | Inhibitor | / | Unkown |
| HY-131067 | EMI56 | Inhibitor | 99.36% | Unkown |
| HY-152852 | Mefatinib free base | Inhibitor | 99.40% | Unkown |
| HY-138627 | AST5902 | Inhibitor | / | Unkown |
| HY-147183 | JBJ-09-063 | Inhibitor | / | Unkown |
| HY-115716 | EGFR-IN-17 | Inhibitor | 98.18% | Unkown |
| HY-139300A | Epitinib succinate | Inhibitor | 99.01% | Unkown |
| HY-132842A | (S)-Sunvozertinib | Inhibitor | 99.05% | Unkown |
| HY-130608 | Mutated EGFR-IN-3 | Inhibitor | / | Unkown |
| HY-147941 | MS9427 | Degrader | 95.29% | Unkown |
| HY-P992138 | Vadalentamig | Inhibitor | 95.29% | Unkown |
| HY-101958 | Tyrphostin 25 | Inhibitor | 99.00% | Unkown |
| HY-P3744 | pp60v-src Autophosphorylation site | 99.93% | Unkown | |
| HY-129510 | 4-Methyl erlotinib | Inhibitor | 99.34% | Unkown |
| HY-135805 | JBJ-04-125-02 | Inhibitor | / | Unkown |
| HY-150610 | EGFR-IN-69 | Inhibitor | 99.58% | Unkown |
| HY-19617B | EGFR-IN-1 TFA | Inhibitor | 99.38% | Unkown |
| HY-P992128 | Rinumafusp alfa | Inhibitor | 97.09% | Unkown |
| HY-111452 | EGFR-IN-85 | Inhibitor | / | Unkown |
| HY-U00002 | ZD-4190 | Inhibitor | 98.08% | Unkown |
| HY-145960 | MC-Val-Cit-PAB-Amide-TLR7 agonist 4 | Agonist | 99.39% | Unkown |
| HY-101007A | (+)-Tyrphostin B44 | Inhibitor | 99.10% | Unkown |
| HY-14347 | EBE-A22 | Control | 99.76% | Unkown |
| HY-164387 | Sutetinib | Inhibitor | 99.27% | Unkown |
| HY-E70715 | ERBB2 775YVMA776 Recombinant Human Active Protein Kinase | / | Unkown | |
| HY-156912 | Tyrosine kinase-IN-7 | Inhibitor | 99.25% | Unkown |
| HY-12008S | Erlotinib-d6 hydrochloride | Inhibitor | 98.13% | Unkown |
| HY-100499 | Tyrphostin AG 528 | Inhibitor | 98.0% | Unkown |
| HY-155005 | EGFR mutant-IN-2 | Inhibitor | 97.0% | Unkown |
| HY-161618 | MJ04 | Inhibitor | 98.08% | Unkown |
| HY-138072 | EMI1 | Inhibitor | 99.45% | Unkown |
| HY-13272S2 | Dacomitinib-d10 dihydrochloride | Inhibitor | ≥95.0% | Unkown |
| HY-103439 | GW583340 dihydrochloride | Inhibitor | / | Unkown |
| HY-10346A | AV-412 free base | Inhibitor | 98.10% | Unkown |
| HY-144677 | pan-HER-IN-2 | Inhibitor | 98.10% | Unkown |
| HY-155358 | Os30 | Inhibitor | 98.34% | Unkown |
| HY-N6651 | Isocryptotanshinone | Inhibitor | ≥98.0% | Unkown |
| HY-131088 | N3-PEG8-Phe-Lys-PABC-Gefitinib | Inhibitor | / | Unkown |
| HY-162254 | EGFR/ACK1-IN-1 | Inhibitor | 98.19% | Unkown |
| HY-126850 | 4-Epidoxycycline | / | Unkown | |
| HY-12872B | Nazartinib S-enantiomer | 95.10% | Unkown | |
| HY-B0794A | AZ7550 hydrochloride | Inhibitor | 98.66% | Unkown |
| HY-183682 | AZ14289671 | Inhibitor | 98.99% | Unkown |
| HY-149636 | Multi-target kinase inhibitor 2 | Inhibitor | 99.82% | Unkown |
| HY-15772S1 | Osimertinib-13C,d3 | 99.14% | Unkown | |
| HY-50895S1 | Gefitinib-d6 | Inhibitor | 98.2% | Unkown |
| HY-158310 | SOS1/EGFR-IN-1 | Inhibitor | 99.54% | Unkown |
| HY-147219 | SIAIS164018 | Degrader | / | Unkown |
| HY-157413 | YS-67 | Inhibitor | 99.41% | Unkown |
| HY-131088A | N3-PEG8-Phe-Lys-PABC-Gefitinib TFA | Inhibitor | / | Unkown |
| HY-P2673 | Lys-Arg-Thr-Leu-Arg-Arg | / | Unkown | |
| HY-170928 | DA-0157 | Inhibitor | 99.59% | Unkown |
| HY-156741 | EGFR-IN-87 | Inhibitor | / | Unkown |
| HY-151048 | JBJ-07-149 | Inhibitor | 99.09% | Unkown |
| HY-N10103 | Neoschaftoside | Modulator | 98.04% | Unkown |
| HY-183068 | AP4-43 | Inhibitor | 99.76% | Unkown |
| HY-15772S3 | Asandeutertinib | Inhibitor | 99.75% | Unkown |
| HY-108931 | AG 1406 | Inhibitor | 99.03% | Unkown |
| HY-126319 | SU5204 | Inhibitor | 99.46% | Unkown |
| HY-108486 | Herbimycin A | Degrader | 99% | Unkown |
| HY-10261S | Afatinib-d6 | Inhibitor | 99.0% | Unkown |
| HY-155285 | YS-363 | Inhibitor | 99.52% | Unkown |
| HY-P2673A | Lys-Arg-Thr-Leu-Arg-Arg acetate | / | Unkown | |
| HY-153111 | EGFR/HER2-IN-9 | Inhibitor | 98.73% | Unkown |
| HY-147858A | PROTAC EGFR degrader 7 diTFA | Degrader | 97.15% | Unkown |
| HY-12872A | Nazartinib mesylate | Inhibitor | / | Unkown |
| HY-B0794S | AZ7550-d5 | Inhibitor | / | Unkown |
| HY-P990698 | Umizortamig | 96.90% | Unkown | |
| HY-21291 | SU-4313 | Modulator | 99.31% | Unkown |
| HY-123766 | EGFR-IN-99 | Inhibitor | 98.09% | Unkown |
| HY-W001520 | 1-Methyl-1H-pyrrolo[2,3-b]pyridine | / | Unkown | |
| HY-W109039 | EGFR ligand-15 | 97.03% | Unkown | |
| HY-164476 | ES-072 | Inhibitor | 98.05% | Unkown |
| HY-P992130 | Rolditamig | Inhibitor | 95.26% | Unkown |
| HY-185832 | SYS6010 | Inhibitor | / | Unkown |
| HY-185816 | TQB2102 | Inhibitor | / | Unkown |
| HY-135914 | JBJ-02-112-05 | Inhibitor | / | Unkown |
| HY-18750A | Zorifertinib hydrochloride | Inhibitor | / | Unkown |
| HY-19981B | Derazantinib dihydrochloride | Inhibitor | / | Unkown |
| HY-100520 | EGFR-IN-2 | Inhibitor | / | Unkown |
| HY-142283 | Dosimertinib | Inhibitor | / | Unkown |
| HY-143734 | HER2-IN-6 | / | Unkown | |
| HY-B0793S1 | AZ-5104-d2 | Inhibitor | / | Unkown |
| HY-125841 | EGFR mutant-IN-1 | Inhibitor | / | Unkown |
| HY-132883 | EGFR/CSC-IN-1 | Inhibitor | / | Unkown |
| HY-138298C | Trastuzumab deruxtecan (DAR4) | Inhibitor | / | Unkown |
| HY-144048 | EGFR-IN-31 | / | Unkown | |
| HY-139920A | Oritinib mesylate | Inhibitor | / | Unkown |
| HY-163354 | EGFR-IN-103 | Inhibitor | / | Unkown |
| HY-128860 | Mutated EGFR-IN-2 | Inhibitor | / | Unkown |
| HY-168968S | ZJY-54 | Inhibitor | / | Unkown |
| HY-112806 | ST8155AA1 | / | Unkown | |
| HY-138746 | EGFR-IN-15 | Inhibitor | 96.21% | Unkown |
| HY-131066 | EMI48 | Inhibitor | 99.45% | Unkown |
| HY-152852A | Mefatinib | Inhibitor | 98.90% | Unkown |
| HY-123726 | ErbB-1/ErbB-2 tyrosine kinase-IN-1 | / | Unkown | |
| HY-137433A | Befotertinib mesylate | Inhibitor | / | Unkown |
| HY-10407G | SU 5402 (GMP) | Inhibitor | / | Unkown |
| HY-147303 | Sacibertinib | Inhibitor | / | Unkown |
| HY-115951 | EGFR/HER2-IN-2 | Inhibitor | / | Unkown |
| HY-147407 | Imbotolimod | Inhibitor | / | Unkown |
| HY-E70711 | EGFR T790M/L858R Recombinant Human Active Protein Kinase | / | Unkown | |
| HY-181776 | c-Met-IN-31 | Inhibitor | / | Unkown |
| HY-187533 | EGFR AUTOTAC-1 | Degrader | / | Unkown |
| HY-179600 | Dyrk1A-IN-16 | Inhibitor | / | Unkown |
| HY-181657 | EGFR-IN-200 | Inhibitor | / | Unkown |
| HY-149344 | Anticancer agent 133 | Inhibitor | / | Unkown |
| HY-162148 | HNPMI | Inhibitor | 99.57% | Unkown |
| HY-183373 | EGFR/PARP-1-IN-1 | Inhibitor | / | Unkown |
| HY-151981 | EGFR-IN-74 | Inhibitor | / | Unkown |
| HY-152019 | EGFR/C797S-IN-1 | Inhibitor | / | Unkown |
| HY-131710 | PDE5-IN-3 | Inhibitor | / | Unkown |
| HY-152144 | EGFR-IN-75 | Inhibitor | / | Unkown |
| HY-162623 | EGFR/HER2-IN-15 | Inhibitor | / | Unkown |
| HY-161145 | EGFR/microtubule-IN-1 | Inhibitor | / | Unkown |
| HY-147996 | EGFR-IN-67 | Inhibitor | / | Unkown |
| HY-180536 | HB-EGF-IN-1 | Inhibitor | / | Unkown |
| HY-161031 | EGFR-IN-93 | Inhibitor | / | Unkown |
| HY-177379 | EGFR ligand-14 | / | Unkown | |
| HY-142283CS | N-Methyl-dosimertinib-d5 | / | Unkown | |
| HY-161269 | EGFR-IN-101 | Inhibitor | / | Unkown |
| HY-175635 | EGFR/VEGFR2-IN-6 | Inhibitor | / | Unkown |
| HY-175531 | EGFR-IN-169 | Inhibitor | / | Unkown |
| HY-P2548 | pp60 (v-SRC) Autophosphorylation Site, Phosphorylated | / | Unkown | |
| HY-E70703 | EGFR d752-759 Recombinant Human Active Protein Kinase | / | Unkown | |
| HY-174232 | EGFR/CA-IX-IN-1 | Inhibitor | / | Unkown |
| HY-158988 | EGFR-IN-114 | Inhibitor | / | Unkown |
| HY-168112 | EGFR-IN-127 | Inhibitor | / | Unkown |
| HY-161602 | EGFR/HER2-IN-13 | Inhibitor | / | Unkown |
| HY-161045 | T-1-DOCA | Inhibitor | / | Unkown |
| HY-RS04470 | Erbb3 Mouse Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-181251 | EGFR-IN-195 | Inhibitor | / | Unkown |
| HY-163453 | HER2-IN-19 | Inhibitor | / | Unkown |
| HY-10368 | EGFR/VEGFR2-IN-4 | Inhibitor | / | Unkown |
| HY-182264 | Masoprocol tetrapivalate | Inhibitor | / | Unkown |
| HY-175864 | EGFR-IN-173 | Inhibitor | / | Unkown |
| HY-173188 | EGFR-IN-154 | Inhibitor | / | Unkown |
| HY-172961 | EGFR-IN-162 | Inhibitor | / | Unkown |
| HY-135216 | Antiproliferative agent-54 | Inhibitor | / | Unkown |
| HY-161146 | EGFR-IN-100 | Inhibitor | / | Unkown |
| HY-P990049A | Becotatug (powder) | Inhibitor | / | Unkown |
| HY-182914 | NGI-189 | Inhibitor | 99.29% | Unkown |
| HY-E70698 | EGFR d746-750/C797S Recombinant Human Active Protein Kinase | / | Unkown | |
| HY-13595R | Chrysophanol (Standard) | Inhibitor | / | Unkown |
| HY-P5258 | Oligopeptide-41 | Inducer | 98.05% | Unkown |
| HY-162099 | VEGFR-IN-4 | Inhibitor | / | Unkown |
| HY-157912 | EGFR-IN-102 | Inhibitor | / | Unkown |
| HY-162360 | EGFR-IN-109 | Inhibitor | / | Unkown |
| HY-187838S | Adonertinib | Inhibitor | / | Unkown |
| HY-172877 | EGFR/BRAFV600E-IN-5 | Inhibitor | / | Unkown |
| HY-178942 | EGFR/VEGFR2-IN-9 | Inhibitor | / | Unkown |
| HY-E70699 | EGFR d746-750/T790M/C797S Recombinant Human Active Protein Kinase | / | Unkown | |
| HY-179522 | EGFR-IN-186 | Inhibitor | / | Unkown |
| HY-146238 | EGFR/HER2/TS-IN-1 | Inhibitor | / | Unkown |
| HY-168492 | TrxR/EGFR-IN-1 | Inhibitor | / | Unkown |
| HY-171884 | BI-8128 | Inhibitor | / | Unkown |
| HY-144054 | EGFR-IN-37 | Inhibitor | / | Unkown |
| HY-173619 | EGFR-IN-160 | Inhibitor | / | Unkown |
| HY-160564 | ZNL-0056 | Inhibitor | / | Unkown |
| HY-168469 | EGFR-IN-148 | Inhibitor | / | Unkown |
| HY-W008914 | (E/Z)-CP-724714 | Inhibitor | / | Unkown |
| HY-153744 | JGK-068S | Inhibitor | / | Unkown |
| HY-172091 | CZY43 | Degrader | / | Unkown |
| HY-18213 | EGFR-IN-9 | Inhibitor | 98.69% | Unkown |
| HY-174841 | EGFR/HER2-IN-19 | Inhibitor | / | Unkown |
| HY-185227 | EphB4-IN-1 | Inhibitor | / | Unkown |
| HY-103566A | LY456236 free base | Inhibitor | / | Unkown |
| HY-156470 | Multi-kinase-IN-6 | Inhibitor | / | Unkown |
| HY-146170 | Anticancer agent 69 | Inhibitor | / | Unkown |
| HY-178448 | EGFR-IN-178 | Inhibitor | / | Unkown |
| HY-P5742 | ELAAWCRWGFLLALLPPGIAG | / | Unkown | |
| HY-181056 | EGFR/COX-2-IN-3 | Inhibitor | 99.76% | Unkown |
| HY-163434 | PRMT5/EGFR-IN-1 | Inhibitor | / | Unkown |
| HY-181775 | VEGFR-2/c-Met/EGFR-IN-1 | Inhibitor | / | Unkown |
| HY-P10659 | Self-assembling peptide pY1 | / | Unkown | |
| HY-116277 | Z118332870 | Inhibitor | / | Unkown |
| HY-175173 | EGFR-IN-166 | Inhibitor | / | Unkown |
| HY-144760 | EGFR-IN-3 | Inducer | / | Unkown |
| HY-175171 | Anticancer agent 276 | Inhibitor | / | Unkown |
| HY-178242 | PROTAC EGFR degrader 16 | Degrader | / | Unkown |
| HY-158153 | EGFR-IN-108 | Inhibitor | / | Unkown |
| HY-172534 | BPN-01 | Substrate | / | Unkown |
| HY-P5745A | TYVPANASL TFA | / | Unkown | |
| HY-173367 | Anticancer agent 271 | Inhibitor | / | Unkown |
| HY-183277 | EGFR-IN-209 | Inhibitor | / | Unkown |
| HY-181502 | EGFR-IN-197 | Inhibitor | / | Unkown |
| HY-181097 | EGFR-IN-192 | Inhibitor | / | Unkown |
| HY-50898S2 | Lapatinib-d5 | Inhibitor | / | Unkown |
| HY-178311 | EGFR Ligand-Linker Conjugates 4 | Ligand | / | Unkown |
| HY-173038 | EGFR-IN-151 | Inhibitor | / | Unkown |
| HY-160087 | SG3376 | Ligand | / | Unkown |
| HY-147741 | DPPY | Inhibitor | / | Unkown |
| HY-178142 | Multi-kinase-IN-7 | Inhibitor | / | Unkown |
| HY-RS04467 | Erbb2 Mouse Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-162589 | Lw13 | Inhibitor | / | Unkown |
| HY-144052 | EGFR-IN-35 | Inhibitor | / | Unkown |
| HY-181714 | EGFR-IN-203 | Inhibitor | / | Unkown |
| HY-151377 | RET-IN-19 | Inhibitor | / | Unkown |
| HY-N1988R | Cucurbitacin IIa (Standard) | Inhibitor | / | Unkown |
| HY-179098 | Multi-target kinase-IN-8 | Inhibitor | / | Unkown |
| HY-178057 | EGFR-IN-176 | Inhibitor | / | Unkown |
| HY-P11761 | HYNIC-H10F | Ligand | / | Unkown |
| HY-171252 | EGFR-IN-145 | Inhibitor | / | Unkown |
| HY-144097 | HER2-IN-8 | Inhibitor | / | Unkown |
| HY-158313 | PROTAC EGFR degrader 13 | Inhibitor | / | Unkown |
| HY-185833 | ADC Control Human IgG1-JSSW-001 | Inhibitor | / | Unkown |
| HY-118175 | RG 14921 | Inhibitor | / | Unkown |
| HY-169346 | Pred17 | Inhibitor | / | Unkown |
| HY-172469 | DSPE-PEG1000-GE11 | / | Unkown | |
| HY-177009 | Tucatinib analog B | Ligand | / | Unkown |
| HY-50896S1 | Erlotinib-13C6 | Inhibitor | / | Unkown |
| HY-157402 | Topoisomerase II/EGFR-IN-1 | / | Unkown | |
| HY-184720 | VEGFR-2-IN-89 | Inhibitor | / | Unkown |
| HY-155074 | EGFR-IN-79 | Inhibitor | / | Unkown |
| HY-E70704 | EGFR G719C Recombinant Human Active Protein Kinase | / | Unkown | |
| HY-184311 | EGFR-IN-214 | Inhibitor | / | Unkown |
| HY-402309 | IGF-1R modulator 1 | Modulator | / | Unkown |
| HY-143323 | HER2-IN-9 | Inhibitor | / | Unkown |
| HY-163402 | EGFR-IN-108 chloride | Inhibitor | / | Unkown |
| HY-163377 | AZ5385 | Inhibitor | / | Unkown |
| HY-149401 | EGFR-IN-82 | Inhibitor | / | Unkown |
| HY-143445 | EGFR-IN-48 | Inhibitor | / | Unkown |
| HY-175316 | EGFR-IN-168 | Inhibitor | / | Unkown |
| HY-P1085 | Epidermal Growth Factor Receptor Peptide (985-996) | Chemical | / | Unkown |
| HY-170497 | EGFR-IN-140 | Inhibitor | / | Unkown |
| HY-50898S3 | Lapatinib-d4-1 | Inhibitor | / | Unkown |
| HY-182005 | EGFR/VEGFR2-IN-12 | Inhibitor | / | Unkown |
| HY-159519 | EGFR/HER2-IN-16 | Inhibitor | / | Unkown |
| HY-P11757 | Cyclo[K(N3)larllt] | Ligand | / | Unkown |
| HY-175297 | EGFR T790M/VEGFR-2-IN-1 | Inhibitor | / | Unkown |
| HY-103437 | EGFR-IN-80 | Inhibitor | / | Unkown |
| HY-13314A | Tesevatinib tosylate | Inhibitor | / | Unkown |
| HY-155118 | EGFR-IN-81 | Inhibitor | / | Unkown |
| HY-151156 | EGFR/HER2-IN-6 | Inhibitor | / | Unkown |
| HY-176744 | HER2-IN-22 | Inhibitor | / | Unkown |
| HY-172795 | EGFR-IN-158 | Inhibitor | / | Unkown |
| HY-180922 | EGFR kinase-IN-8 | Inhibitor | / | Unkown |
| HY-170787 | TZEP7 | Inhibitor | / | Unkown |
| HY-153557 | HER2-IN-13 | Inhibitor | / | Unkown |
| HY-172966 | EG31 | Inhibitor | / | Unkown |
| HY-157399 | EGFR/HER2-IN-10 | Inhibitor | / | Unkown |
| HY-103439A | GW583340 | Inhibitor | / | Unkown |
| HY-157398 | EGFR T790M/L858R-IN-3 | Inhibitor | / | Unkown |
| HY-15268 | PP487 | Inhibitor | / | Unkown |
| HY-146228 | HSP90-IN-13 | Inhibitor | / | Unkown |
| HY-184301 | EGFR/HER2-IN-20 | Inhibitor | / | Unkown |
| HY-B0793GL | AZ-5104 (GMP Like) | Inhibitor | / | Unkown |
| HY-175220 | 4-TCPA | Inhibitor | / | Unkown |
| HY-147862 | EGFR-IN-62 | Inhibitor | / | Unkown |
| HY-142680 | EGFR-IN-23 | Inhibitor | / | Unkown |
| HY-180541 | EGFR-IN-190 | Inhibitor | / | Unkown |
| HY-162323 | EGFR-IN-106 | Inhibitor | / | Unkown |
| HY-163880 | EGFR-IN-119 | Inhibitor | / | Unkown |
| HY-149824 | EGFR T790M/L858R-IN-2 | Inhibitor | 99.66% | Unkown |
| HY-146239 | EGFR/HER2/TS-IN-2 | Inhibitor | / | Unkown |
| HY-142679 | EGFR-IN-22 | Inhibitor | / | Unkown |
| HY-172179 | EGFR/VEGFR2-IN-5 | Inhibitor | / | Unkown |
| HY-161731 | DS08701581 | Inhibitor | / | Unkown |
| HY-157994 | EGFR WT/T790M-IN-2 | Inhibitor | / | Unkown |
| HY-164392 | TAS-121 | Inhibitor | / | Unkown |
| HY-147992 | EGFR/HER2-IN-4 | Inhibitor | / | Unkown |
| HY-144051 | EGFR-IN-34 | Inhibitor | / | Unkown |
| HY-175162 | EGFR ligand-20 | Ligand | / | Unkown |
| HY-103629 | PROTAC Her3 Degrader-1 | Inhibitor | / | Unkown |
| HY-168577 | KRAS G12D inhibitor 25 | Degrader | / | Unkown |
| HY-147997 | EGFR-IN-68 | Inhibitor | / | Unkown |
| HY-183120 | EGFR T790M/FAK-IN-2 | Inhibitor | / | Unkown |
| HY-P10569 | Biotin HER-2 substrate peptide | / | Unkown | |
| HY-138298B | Trastuzumab deruxtecan (DAR2) | Inhibitor | / | Unkown |
| HY-183754 | EGFR-IN-213 | Inhibitor | / | Unkown |
| HY-18957A | rel-Lifirafenib | Control | / | Unkown |
| HY-175009 | MRC-G-001 | Inhibitor | / | Unkown |
| HY-178157 | Multi-target kinase-IN-7 | Inhibitor | / | Unkown |
| HY-174415 | ZSH-2117 | Degrader | / | Unkown |
| HY-50898S5 | Lapatinib-13C,d7 | Inhibitor | / | Unkown |
| HY-137028 | 2′-Thioadenosine | Inhibitor | / | Unkown |
| HY-161603 | EGFR/HER2-IN-14 | Inhibitor | / | Unkown |
| HY-100636A | Gefitinib N-oxide hydrochloride | Inhibitor | / | Unkown |
| HY-P5742A | ELAAWCRWGFLLALLPPGIAG TFA | / | Unkown | |
| HY-143901 | EGFR-IN-40 | Inhibitor | / | Unkown |
| HY-156116 | EGFR/CDK2-IN-4 | Inhibitor | / | Unkown |
| HY-169568 | EGFR-IN-147 | Inhibitor | / | Unkown |
| HY-182031 | JS04 | Inhibitor | / | Unkown |
| HY-163006 | EGFR/c-Met-IN-1 | Inhibitor | / | Unkown |
| HY-168073 | EGFR/VEGFR2-IN-1 | Inhibitor | / | Unkown |
| HY-146473 | EGFR-IN-53 | Inhibitor | / | Unkown |
| HY-169982 | EGFR-IN-136 | Inhibitor | / | Unkown |
| HY-169427 | FRF-06-057 | Inhibitor | / | Unkown |
| HY-147248 | Opadotina | Inhibitor | / | Unkown |
| HY-179485 | EGFR/VEGFR2-IN-10 | Inhibitor | / | Unkown |
| HY-183788 | EGFR-IN-212 | Inhibitor | / | Unkown |
| HY-158154 | EGFR-IN-110 | Inhibitor | / | Unkown |
| HY-172780 | EGFR-IN-161 | Inhibitor | / | Unkown |
| HY-180154 | EGFR/BRAFV600E-IN-6 | Inhibitor | / | Unkown |
| HY-N9684 | Degalactotigonin | Inhibitor | / | Unkown |
| HY-150908 | Brigatinib A | Ligand | / | Unkown |
| HY-149518 | EGFR/BRAFV600E-IN-3 | Inhibitor | / | Unkown |
| HY-144044 | EGFR-IN-30 | Inhibitor | / | Unkown |
| HY-137786 | EGFR-IN-16 | Inhibitor | / | Unkown |
| HY-178939 | EGFR-IN-181 | Inhibitor | / | Unkown |
| HY-176556 | EGFR-IN-167 | Inhibitor | / | Unkown |
| HY-100663 | Gefitinib impurity 2 | 99.56% | Unkown | |
| HY-161067 | EGFR-IN-96 | Inhibitor | / | Unkown |
| HY-P1828 | EGFRvIII peptide (PEPvIII) | / | Unkown | |
| HY-144444 | NSC381467 | Inhibitor | / | Unkown |
| HY-157526 | EGFR-TK-IN-1 | Inhibitor | / | Unkown |
| HY-156033 | EGFR-IN-88 | Inhibitor | / | Unkown |
| HY-107450 | PROTAC Her3-binding moiety 2 | Inhibitor | / | Unkown |
| HY-181777 | Mal-Pip-ValCit-PAB-AZ7550 | Inhibitor | / | Unkown |
| HY-181093 | EGFR-IN-191 | Inhibitor | / | Unkown |
| HY-172111 | EGFR-IN-144 | Inhibitor | / | Unkown |
| HY-189142 | EGFR-IN-217 | Inhibitor | / | Unkown |
| HY-167948 | Dacomitinib metabolite M1/2 | Inhibitor | / | Unkown |
| HY-169309 | EGFR-IN-133 | Inhibitor | / | Unkown |
| HY-138627B | AST5902 mesylate | Inhibitor | / | Unkown |
| HY-144445 | NSC114126 | Inhibitor | / | Unkown |
| HY-161320 | EGFR-IN-105 | Inhibitor | / | Unkown |
| HY-138298D | Trastuzumab deruxtecan (DAR6) | Inhibitor | / | Unkown |
| HY-149407 | Multi-kinase-IN-4 | Inhibitor | / | Unkown |
| HY-156114 | EGFR/CDK2-IN-2 | Inhibitor | / | Unkown |
| HY-175292 | EGFR WT/T790M-IN-3 | Inhibitor | / | Unkown |
| HY-146138 | EGFR-IN-57 | Inhibitor | / | Unkown |
| HY-147825 | EGFR/BRAFV600E-IN-1 | Inhibitor | / | Unkown |
| HY-112823S | Almonertinib-d6 | Inhibitor | / | Unkown |
| HY-146136 | EGFR-IN-56 | Inhibitor | / | Unkown |
| HY-178313 | EGFR ligand-18 | Degrader | / | Unkown |
| HY-170543 | Dual Galectin-3/EGFR-IN-1 | Inhibitor | / | Unkown |
| HY-P12120 | ErbB-2-binding peptide-2 | Ligand | / | Unkown |
| HY-P10995 | TAT-327 | Inhibitor | / | Unkown |
| HY-10188 | SKS-927 | Inhibitor | / | Unkown |
| HY-187692 | IRAK4-IN-35 | Inhibitor | / | Unkown |
| HY-149695 | EGFR-IN-91 | Inhibitor | / | Unkown |
| HY-168559 | EGFR-IN-131 | Inhibitor | / | Unkown |
| HY-182817 | Len-604 | Inhibitor | / | Unkown |
| HY-156991 | NODAGA-NHS | / | Unkown | |
| HY-183123 | EGFR T790M/FAK-IN-1 | Inhibitor | / | Unkown |
| HY-160613 | EGFR/HER2-IN-11 | Inhibitor | / | Unkown |
| HY-178440 | EGFR/COX-2-IN-2 | Inhibitor | / | Unkown |
| HY-112334 | EGFR-IN-198 | Inhibitor | / | Unkown |
| HY-177380 | EGFR ligand-14-PEG3-Boc | / | Unkown | |
| HY-163000 | EGFR-IN-129 | Inhibitor | / | Unkown |
| HY-173492 | EGFR-IN-156 | Inhibitor | / | Unkown |
| HY-164413 | CLM3 | Inhibitor | / | Unkown |
| HY-178005 | EGFR-IN-174 | Inhibitor | / | Unkown |
| HY-17654 | BIEGi-1 | Inhibitor | / | Unkown |
| HY-155227 | ALK/EGFR-IN-1 | Inhibitor | / | Unkown |
| HY-176788 | EGFR Ligand-Linker Conjugates 1 | Inhibitor | / | Unkown |
| HY-179049 | EGFR/tubulin-IN-1 | Inhibitor | / | Unkown |
| HY-151882 | EGFR-IN-73 | Inhibitor | / | Unkown |
| HY-146423 | PROTAC EGFR degrader 6 | Degrader | / | Unkown |
| HY-173218 | anti-NSCLC agent-1 | Inhibitor | / | Unkown |
| HY-168627 | EGFR-IN-135 | Inhibitor | / | Unkown |
| HY-172897 | EGFR/DHFR-IN-2 | Inhibitor | / | Unkown |
| HY-168876 | AZ14240475 | Inhibitor | / | Unkown |
| HY-W714853 | (+)-Theta-cypermethrin | Ligand | / | Unkown |
| HY-183292 | SH-1092 | Inhibitor | / | Unkown |
| HY-180242 | EGFR/CDK2-IN-5 | Inhibitor | / | Unkown |
| HY-172623 | EGFR/HER2-IN-17 | Inhibitor | / | Unkown |
| HY-P11944 | Peptide 22 | Chemical | / | Unkown |
| HY-182064 | EGFR-IN-206 | Inhibitor | / | Unkown |
| HY-147967 | EGFR-IN-63 | Inhibitor | / | Unkown |
| HY-158176 | EGFR T790M/L858R-IN-5 | Inhibitor | / | Unkown |
| HY-144056 | EGFR-IN-39 | Inhibitor | / | Unkown |
| HY-152852S | Mefatinib-d6 free base | Inhibitor | / | Unkown |
| HY-10261AS | Afatinib-d6 dimaleate | Inhibitor | / | Unkown |
| HY-180917 | PROTAC EGFR degrader 17 | Degrader | / | Unkown |
| HY-185276 | EGFR-IN-204 | Inhibitor | 98.57% | Unkown |
| HY-N3634 | Corylifol C | / | Unkown | |
| HY-161923 | EGFR-IN-120 | Inhibitor | / | Unkown |
| HY-158177 | EGFR T790M/L858R-IN-6 | Inhibitor | / | Unkown |
| HY-144441 | NSC81111 | Inhibitor | / | Unkown |
| HY-P11078 | LARLLT | / | Unkown | |
| HY-179143 | EGFR-IN-185 | Inhibitor | / | Unkown |
| HY-142681 | EGFR-IN-28 | Inhibitor | / | Unkown |
| HY-147798 | EGFR/HER2/CDK9-IN-3 | Inhibitor | / | Unkown |
| HY-183310 | EGFR-IN-210 | Inhibitor | / | Unkown |
| HY-156639 | EGFR/ErbB-2 inhibitor-1 | Inhibitor | / | Unkown |
| HY-158178 | EGFR T790M/L858R-IN-7 | Inhibitor | / | Unkown |
| HY-170968 | EGFR-IN-150 | Inhibitor | / | Unkown |
| HY-181829 | Ctx-L3 | Degrader | / | Unkown |
| HY-19730A | Olmutinib hydrochloride | Inhibitor | / | Unkown |
| HY-163663 | AZ14133346 | Inhibitor | / | Unkown |
| HY-E70709 | EGFR T790M Recombinant Human Active Protein Kinase | / | Unkown | |
| HY-P10648 | Herceptide | / | Unkown | |
| HY-189075 | I-0436650 | Inhibitor | / | Unkown |
| HY-143733 | HER2-IN-5 | Inhibitor | / | Unkown |
| HY-163726 | GLUT1/EGFR-IN-1 | Inhibitor | 99.75% | Unkown |
| HY-165394 | Melafolone | Inhibitor | / | Unkown |
| HY-156097 | Anticancer agent 158 | Inhibitor | / | Unkown |
| HY-177270 | CHNQD-01281 | Modulator | / | Unkown |
| HY-E70701 | EGFR d747-749/A750P Recombinant Human Active Protein Kinase | / | Unkown | |
| HY-B0793G | AZ-5104 (GMP) | Inhibitor | / | Unkown |
| HY-179529 | EGFR/InhA-IN-1 | Inhibitor | / | Unkown |
| HY-13272S3 | Dacomitinib-d10 | Inhibitor | / | Unkown |
| HY-176938 | AfaPhos1 | Inhibitor | / | Unkown |
| HY-187334 | EGFR-IN-216 | Inhibitor | / | Unkown |
| HY-174231 | EGFR-IN-163 | Inhibitor | / | Unkown |
| HY-178116 | HER2-IN-23 | Inhibitor | / | Unkown |
| HY-184497 | PROTAC EGFR degrader 18 | Degrader | / | Unkown |
| HY-151162 | HER2-IN-12 | Inhibitor | / | Unkown |
| HY-164056 | EGFR T790M/L858R-IN-8 | Inhibitor | 99.20% | Unkown |
| HY-150782 | UNC-CA359 | Inhibitor | / | Unkown |
| HY-155178 | Antiproliferative agent-34 | Inhibitor | / | Unkown |
| HY-168151 | EGFR-IN-128 | Inhibitor | / | Unkown |
| HY-147802 | EGFR-IN-59 | Inhibitor | / | Unkown |
| HY-127067 | Yuanhuadin | Inhibitor | / | Unkown |
| HY-146782 | EGFR-IN-49 | Inhibitor | / | Unkown |
| HY-RS04469 | ERBB3 Human Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-183253 | DL149 | Ligand | / | Unkown |
| HY-184274 | EGFR/c-SRC-IN-1 | Inhibitor | / | Unkown |
| HY-147796 | EGFR/HER2/CDK9-IN-1 | Inhibitor | / | Unkown |
| HY-162891 | EGFR-IN-123 | Inhibitor | / | Unkown |
| HY-175257 | Theophylline-platinum(IV) prodrug-1 | Inhibitor | / | Unkown |
| HY-101960 | (Z)-Tyrphostin A51 | Inhibitor | / | Unkown |
| HY-172471 | DSPE-PEG5000-GE11 | / | Unkown | |
| HY-P11613 | DOTA-WC8 | Ligand | / | Unkown |
| HY-116059 | EGFR-IN-199 | Inhibitor | / | Unkown |
| HY-172470A | DSPE-PEG3400-GE11 | / | Unkown | |
| HY-175809 | SRT6 | Inhibitor | / | Unkown |
| HY-P11752 | Cyclo(KLARLLT) | Ligand | / | Unkown |
| HY-184719 | VEGFR-2-IN-88 | Inhibitor | / | Unkown |
| HY-180964 | Lys-PEG3-BA | Degrader | / | Unkown |
| HY-180965 | Pro-PEG3-BA | Degrader | / | Unkown |
| HY-161866 | EGFR-IN-118 | Inhibitor | / | Unkown |
| HY-163418 | HER2-IN-17 | Inhibitor | / | Unkown |
| HY-101959 | Tyrphostin AG213 | Inhibitor | / | Unkown |
| HY-184116 | A2AR/EGFR-IN-1 | Inhibitor | / | Unkown |
| HY-142678 | EGFR-IN-21 | Inhibitor | / | Unkown |
| HY-181491 | Tubulin-IN-64 | Inhibitor | / | Unkown |
| HY-142283BS | N-Desmethyl dosimertinib-d5 | / | Unkown | |
| HY-147794 | CDK9-IN-41 | Inhibitor | 98.84% | Unkown |
| HY-163722 | EGFR/DHFR-IN-1 | Inhibitor | / | Unkown |
| HY-112405 | BPIQ-I | Inhibitor | / | Unkown |
| HY-158969 | EGFR-IN-113 | Inhibitor | / | Unkown |
| HY-161891 | EGFR/Akt-IN-1 | Inhibitor | / | Unkown |
| HY-155969 | EGFR-IN-83 | Inhibitor | / | Unkown |
| HY-163657 | HER2-IN-20 | Inhibitor | / | Unkown |
| HY-173118 | EGFR-IN-152 | Inhibitor | / | Unkown |
| HY-168623 | EGFR-IN-134 | Inhibitor | / | Unkown |
| HY-15772GL | Osimertinib (GMP Like) | Inhibitor | / | Unkown |
| HY-13524A | AG-1478 hydrochloride | Inhibitor | / | Unkown |
| HY-RS04211 | Egfr Rat Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-144794 | EGFR-IN-46 | Inhibitor | / | Unkown |
| HY-175608 | EGFR-IN-171 | Inhibitor | / | Unkown |
| HY-E70696 | EGFR C797S/L858R Recombinant Human Active Protein Kinase | / | Unkown | |
| HY-121828 | TX-1123 | Inhibitor | / | Unkown |
| HY-147995 | EGFR-IN-64 | Inhibitor | / | Unkown |
| HY-208666 | EGFR-IN-215 | Inhibitor | / | Unkown |
| HY-P11590 | WGYRGFYC | Ligand | / | Unkown |
| HY-181142 | Antitumor agent-213 | / | Unkown | |
| HY-149275 | PKM2/PDK1-IN-1 | Inhibitor | / | Unkown |
| HY-175805 | EGFR/HDAC-IN-2 | Inhibitor | / | Unkown |
| HY-155079A | (R)-DZD1516 | Control | 98.80% | Unkown |
| HY-170661 | EGFR-IN-142 | Inhibitor | / | Unkown |
| HY-145823 | EGFR-IN-42 | Inhibitor | / | Unkown |
| HY-RS04473 | Erbb4 Mouse Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-144605 | PROTAC EGFR degrader 3 | Inhibitor | 97.39% | Unkown |
| HY-168655 | EGFR/VEGFR2-IN-3 | Inhibitor | / | Unkown |
| HY-179150 | EGFR-TK-IN-6 | Inhibitor | / | Unkown |
| HY-139884 | EGFR-IN-18 | Inhibitor | / | Unkown |
| HY-172621 | EGFR-IN-159 | Inhibitor | / | Unkown |
| HY-168173 | EGFR-IN-130 | Inhibitor | / | Unkown |
| HY-P10793 | Cyclic(YCDGFYACYMDV) | Inhibitor | / | Unkown |
| HY-183311 | EGFR-IN-211 | Inhibitor | / | Unkown |
| HY-169408 | EGFR-IN-137 | Inhibitor | / | Unkown |
| HY-173500 | MG-3C | Inhibitor | / | Unkown |
| HY-145867 | EGFR-IN-45 | Inhibitor | / | Unkown |
| HY-P10792A | HYNIC-H6F | Ligand | / | Unkown |
| HY-13050A | Sapitinib fumarate | Inhibitor | / | Unkown |
| HY-171958 | PROTAC EGFR degrader 12 | Degrader | / | Unkown |
| HY-169308 | EGFR-IN-132 | Inhibitor | / | Unkown |
| HY-158018 | EGFR-TK-IN-2 | Inhibitor | / | Unkown |
| HY-170665 | EGFR T790M/L858R-IN-9 | Inhibitor | / | Unkown |
| HY-179031 | EGFR/VEGFR2-IN-7 | Inhibitor | / | Unkown |
| HY-180966 | Gly-PEG3-BA | Degrader | / | Unkown |
| HY-182073 | EGFR-IN-207 | Inhibitor | / | Unkown |
| HY-18957B | Lifirafenib maleate | Inhibitor | / | Unkown |
| HY-164489 | KU004 | Inhibitor | / | Unkown |
| HY-181115 | EGFR-IN-193 | Inhibitor | / | Unkown |
| HY-180949 | EGFR-IN-189 | Inhibitor | / | Unkown |
| HY-144050 | EGFR-IN-33 | Inhibitor | / | Unkown |
| HY-129288 | GW837016X | Inhibitor | / | Unkown |
| HY-123891 | NS-062 | Inhibitor | / | Unkown |
| HY-173501 | EGFR-IN-157 | Inhibitor | / | Unkown |
| HY-157166 | EGFR kinase inhibitor 2 | Inhibitor | / | Unkown |
| HY-149633 | EGFR/HER2/DHFR-IN-3 | Inhibitor | / | Unkown |
| HY-150905 | EGFR ligand-2 | Inhibitor | / | Unkown |
| HY-100636 | Gefitinib N-oxide | Inhibitor | / | Unkown |
| HY-178283 | EGFR-IN-177 | Inhibitor | / | Unkown |
| HY-115952 | EGFR/HER2-IN-3 | Inhibitor | / | Unkown |
| HY-162482 | EGFR kinase inhibitor 5 | Inhibitor | / | Unkown |
| HY-172104 | EGFR-IN-143 | Inhibitor | / | Unkown |
| HY-181061 | COX/5-LO-IN-2 | Inhibitor | / | Unkown |
| HY-E70708 | EGFR L861Q Recombinant Human Active Protein Kinase | / | Unkown | |
| HY-115933 | EGFR/BRAF-IN-1 | Inhibitor | / | Unkown |
| HY-164988 | TX2-120-1 | Degrader | / | Unkown |
| HY-109061A | Lazertinib mesylate hydrate | Inhibitor | / | Unkown |
| HY-181923 | IMP-Zn | / | Unkown | |
| HY-169216 | Multi-target kinase inhibitor 3 | Inhibitor | / | Unkown |
| HY-161968 | EGFR/PI3Kα-IN-1 | Inhibitor | / | Unkown |
| HY-W777297 | Lapatinib-13C2,15N Ditosylate | / | Unkown | |
| HY-133453 | PROTAC EGFR degrader 1 | Degrader | / | Unkown |
| HY-144055 | EGFR-IN-38 | Inhibitor | / | Unkown |
| HY-178009 | EGFR-IN-175 | Inhibitor | / | Unkown |
| HY-181701 | EGFR-IN-202 | Inhibitor | / | Unkown |
| HY-168433 | LSD1/EGFR-IN-1 | Inhibitor | / | Unkown |
| HY-10261S1 | Afatinib-d4 | Inhibitor | / | Unkown |
| HY-178353 | EGFR/Cytokine-IN-1 | Inhibitor | / | Unkown |
| HY-146210 | EGFR-IN-50 | Inhibitor | / | Unkown |
| HY-163371 | EGFR WT/T790M-IN-1 | Inhibitor | / | Unkown |
| HY-162300 | EGFR kinase inhibitor 4 | Inhibitor | / | Unkown |
| HY-181766 | EGFR/VEGFR2-IN-11 | Inhibitor | / | Unkown |
| HY-103630 | PROTAC Her3 Degrader-2 | Degrader | / | Unkown |
| HY-162483 | EGFR kinase inhibitor 6 | Inhibitor | / | Unkown |
| HY-181659 | EGFR-IN-201 | Inhibitor | / | Unkown |
| HY-147860 | EGFR-IN-61 | Inhibitor | / | Unkown |
| HY-149556 | MTX-241F | Inhibitor | / | Unkown |
| HY-161030 | EGFR-IN-92 | Inhibitor | / | Unkown |
| HY-118900 | CP-654577 | Inhibitor | / | Unkown |
| HY-175588 | EGFR-IN-170 | Inhibitor | / | Unkown |
| HY-176938A | iAfaPhos1 | / | Unkown | |
| HY-116504 | WB-308 | Inhibitor | / | Unkown |
| HY-151161 | EGFR/HER2-IN-8 | Inhibitor | / | Unkown |
| HY-175837 | EGFR-IN-172 | Inhibitor | / | Unkown |
| HY-178119 | HER4/HER2-IN-1 | Inhibitor | / | Unkown |
| HY-185460 | Pertuzumab-LD3 | Inhibitor | / | Unkown |
| HY-146325 | HSP90-IN-11 | Degrader | / | Unkown |
| HY-168170 | EGFR/VEGFR2-IN-2 | Inhibitor | / | Unkown |
| HY-10261E | (R)-Afatinib | Inhibitor | / | Unkown |
| HY-153557A | HER2-IN-14 | Inhibitor | / | Unkown |
| HY-N16557 | (Rac)-8-Gingerol | Inhibitor | / | Unkown |
| HY-153605 | EGFR-IN-77 | Inhibitor | / | Unkown |
| HY-187517 | Anticancer agent 357 | Inhibitor | / | Unkown |
| HY-179599 | Dyrk1A-IN-15 | Inhibitor | / | Unkown |
| HY-151573 | EGFR/CDK2-IN-1 | Inhibitor | / | Unkown |
| HY-163723 | EGFR-IN-116 | Inhibitor | / | Unkown |
| HY-175011 | EGFR-IN-165 | Inhibitor | / | Unkown |
| HY-116091 | EGFR-IN-451 | Inhibitor | / | Unkown |
| HY-18298 | PD 173955 analog 1 | Inhibitor | / | Unkown |
| HY-145824 | EGFR-IN-43 | Inhibitor | / | Unkown |
| HY-187191 | Autophagy-IN/Ferroptosis inducer-modulator-1 | Inhibitor | / | Unkown |
| HY-185780 | Trastuzumab-DM21 | Inhibitor | / | Unkown |
| HY-146422 | PROTAC EGFR degrader 5 | Degrader | / | Unkown |
| HY-151158 | EGFR/HER2-IN-7 | Inhibitor | / | Unkown |
| HY-163419 | HER2-IN-18 | Inhibitor | / | Unkown |
| HY-163860 | EGFR-TK-IN-3 | Inhibitor | / | Unkown |
| HY-P10224 | G7-18NATE | / | Unkown | |
| HY-172110 | Apoptosis inducer 35 | Inhibitor | / | Unkown |
| HY-149517 | EGFR/BRAFV600E-IN-2 | Inhibitor | / | Unkown |
| HY-P11890 | GPVGPS | Modulator | / | Unkown |
| HY-161785 | EGFR-IN-117 | Inhibitor | / | Unkown |
| HY-P11484 | Myosin Regulatory Light Chain MRCL3 (11-24) | / | Unkown | |
| HY-149846 | SIQ17 | Inhibitor | / | Unkown |
| HY-P11781 | HW12 | Control | / | Unkown |
| HY-E70705 | EGFR G719S Recombinant Human Active Protein Kinase | / | Unkown | |
| HY-164503 | Neptinib | Inhibitor | / | Unkown |
| HY-161632 | PROTAC EGFR degrader 10 | Degrader | / | Unkown |
| HY-146132 | EGFR-IN-55 | Inhibitor | / | Unkown |
| HY-178442 | EGFR-IN-179 | Inhibitor | / | Unkown |
| HY-172156 | EGFR-TK-IN-5 | Inhibitor | / | Unkown |
| HY-143874 | HER2-IN-7 | Inhibitor | / | Unkown |
| HY-159512 | EGFR kinase inhibitor 7 | Inhibitor | / | Unkown |
| HY-146472 | EGFR-IN-52 | Inhibitor | / | Unkown |
| HY-144676 | pan-HER-IN-1 | Inhibitor | / | Unkown |
| HY-RS04474 | Erbb4 Rat Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-173520 | EGFR/HDAC-IN-1 | Inhibitor | / | Unkown |
| HY-170932 | EGFR/COX-2-IN-1 | Inhibitor | / | Unkown |
| HY-175820 | AGW-11 | Inhibitor | / | Unkown |
| HY-162602 | EGFR-IN-115 | Inhibitor | / | Unkown |
| HY-162332 | EGFR-PK/JNK-2-IN-1 | Inhibitor | / | Unkown |
| HY-145844 | EGFR-IN-44 | Inhibitor | / | Unkown |
| HY-104080 | HG-5-88-01 | Inhibitor | / | Unkown |
| HY-162964 | EGFR-IN-126 | Inhibitor | / | Unkown |
| HY-RS04471 | Erbb3 Rat Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-144049 | EGFR-IN-32 | Inhibitor | / | Unkown |
| HY-100064S | O-Desmethyl gefitinib-d8 | Inhibitor | 99.84% | Unkown |
| HY-173314 | EGFR-IN-155 | Inhibitor | / | Unkown |
| HY-E70706 | EGFR L718Q Recombinant Human Active Protein Kinase | / | Unkown | |
| HY-114253 | ODS-2004436 | / | Unkown | |
| HY-163417 | HER2-IN-15 | Inhibitor | / | Unkown |
| HY-164399 | SST0116CL1 | Degrader | / | Unkown |
| HY-W174279 | Tyrphostin 8 | Inhibitor | 99.10% | Unkown |
| HY-155227S | ALK/EGFR-IN-1-d5 | Inhibitor | / | Unkown |
| HY-110328 | PKI-166 hydrochloride | Inhibitor | / | Unkown |
| HY-163420 | HER2-IN-16 | Inhibitor | / | Unkown |
| HY-113549 | Erbstatin | Inhibitor | / | Unkown |
| HY-158016 | Antiproliferative agent-49 | Inhibitor | / | Unkown |
| HY-120412 | SKLB188 | Inhibitor | / | Unkown |
| HY-15772G | Osimertinib (GMP) | Inhibitor | / | Unkown |
| HY-RS04210 | Egfr Mouse Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-170559 | EGFR-IN-141 | Inhibitor | / | Unkown |
| HY-147797 | EGFR/HER2/CDK9-IN-2 | Inhibitor | / | Unkown |
| HY-174414 | EGFR/HER2-IN-18 | Inhibitor | / | Unkown |
| HY-150781 | EGFR-IN-71 | Inhibitor | / | Unkown |
| HY-146154 | EGFR-IN-58 | Inhibitor | / | Unkown |
| HY-117852 | CGP-59326 | Inhibitor | / | Unkown |
| HY-120857 | BPIQ-II hydrochloride | Inhibitor | / | Unkown |
| HY-179039 | EGFR-IN-183 | Inhibitor | / | Unkown |
| HY-181479 | EGFR-IN-196 | Inhibitor | / | Unkown |
| HY-157324 | EGFR-IN-94 | Inhibitor | / | Unkown |
| HY-168064 | EGFR-IN-124 | Inhibitor | / | Unkown |
| HY-182742 | EGFR-IN-208 | Inhibitor | / | Unkown |
| HY-N6678S | (Rac)-Zearalanone-d6 | Degrader | / | Unkown |
| HY-E70695 | EGFR C797S Recombinant Human Active Protein Kinase | / | Unkown | |
| HY-100064S1 | O-Desmethyl gefitinib-d6 | Inhibitor | / | Unkown |
| HY-142519 | EGFR-IN-27 | Inhibitor | / | Unkown |
| HY-162062 | EGFR WT/T790M/L858R-IN-1 | Inhibitor | / | Unkown |
| HY-147994 | EGFR/HER2-IN-5 | Inhibitor | / | Unkown |
| HY-50898CS | Lapatinib-d4 tosylate | Inhibitor | / | Unkown |
| HY-P11760 | HER2-targeted peptide H10 | Ligand | / | Unkown |
| HY-116138 | RG-14467 | Inhibitor | / | Unkown |
| HY-164490 | LS-106 | Inhibitor | / | Unkown |
| HY-143246 | EGFR kinase inhibitor 1 | Inhibitor | / | Unkown |
| HY-171443 | Lyso-Monosialoganglioside GM3 | Inhibitor | / | Unkown |
| HY-183090 | EGFR/VEGFR2-IN-13 | Inhibitor | / | Unkown |
| HY-180823 | Topoisomerase II/EGFR-IN-2 | Inhibitor | / | Unkown |
| HY-E70700 | EGFR d746-750/T790M/C797S/L858R Recombinant Human Active Protein Kinase | / | Unkown | |
| HY-151154 | EGFR/HER2/DHFR-IN-1 | Inhibitor | / | Unkown |
| HY-178955 | EGFR-IN-182 | Inhibitor | / | Unkown |
| HY-153856A | TAS2940 fumarate | Inhibitor | / | Unkown |
| HY-161136 | EGFR/STAT3-IN-1 | Inhibitor | / | Unkown |
| HY-146471 | EGFR-IN-51 | Inhibitor | / | Unkown |
| HY-147826 | EGFR-IN-60 | Inhibitor | / | Unkown |
| HY-157432 | EGFR-IN-97 | Inhibitor | / | Unkown |
| HY-179148 | EGFR-IN-184 | Inhibitor | / | Unkown |
| HY-173164 | EGFR/BRAFV600E-IN-4 | Inhibitor | / | Unkown |
| HY-12008S1 | Erlotinib-13C6 hydrochloride | Inhibitor | / | Unkown |
| HY-146474 | EGFR-IN-54 | Inhibitor | / | Unkown |
| HY-173146 | EGFR-IN-153 | Inhibitor | / | Unkown |
| HY-170438 | EGFR-IN-139 | / | Unkown | |
| HY-155200 | EGFR-IN-84 | Inhibitor | / | Unkown |
| HY-E70702 | EGFR d747-752/P753S Recombinant Human Active Protein Kinase | / | Unkown | |
| HY-159101 | EP26 | Inhibitor | / | Unkown |
| HY-179140 | EGFR/VEGFR2-IN-8 | Inhibitor | / | Unkown |
| HY-141486A | PROTAC PARP/EGFR ligand 1 | / | Unkown | |
| HY-162881 | DS06652923 | Inhibitor | / | Unkown |
| HY-168514 | SOS1/EGFR-IN-2 | Inhibitor | / | Unkown |
| HY-169428 | EGFR-IN-138 | / | Unkown | |
| HY-180196 | EGFR-IN-187 | Inhibitor | / | Unkown |
| HY-W409652 | CLK1/4-IN-2 | Inhibitor | / | Unkown |
| HY-143729 | EGFR-IN-29 | Inhibitor | / | Unkown |
| HY-50898S1 | Lapatinib-d7 dihydrochloride | Inhibitor | / | Unkown |
| HY-114535 | Jaceidin | Inhibitor | / | Unkown |
| HY-P10686 | CH401 peptide | / | Unkown | |
| HY-160828 | O-Desmethyl dacomitinib | Inhibitor | / | Unkown |
| HY-149632 | EGFR/HER2/DHFR-IN-2 | Inhibitor | / | Unkown |
| HY-156457 | EGFR-IN-90 | Inhibitor | / | Unkown |
| HY-174826 | EGFR-IN-164 | Inhibitor | / | Unkown |
| HY-162788 | EGFR-IN-121 | Inhibitor | / | Unkown |
| HY-178824 | EGFR-IN-180 | Inhibitor | / | Unkown |
| HY-177989 | ER121 | Inhibitor | 98.52% | Unkown |
| HY-160682 | EGFR/HER2-IN-12 | Inhibitor | / | Unkown |
| HY-161319 | EGFR-IN-104 | Inhibitor | / | Unkown |
| HY-176279 | Hsp90-IN-42 | Inhibitor | / | Unkown |
| HY-144053 | EGFR-IN-36 | Inhibitor | / | Unkown |
| HY-P10994 | Eps8 peptide 327 | Inhibitor | / | Unkown |
| HY-168427 | Avitinib maleate dihydrate | Inhibitor | / | Unkown |
| HY-181099 | EGFR WT/T790M-IN-4 | Inhibitor | / | Unkown |
| HY-142517 | EGFR-IN-25 | Inhibitor | / | Unkown |
| HY-181166 | EGFR-IN-194 | Inhibitor | / | Unkown |
| HY-158175 | EGFR T790M/L858R-IN-4 | Inhibitor | / | Unkown |
| HY-172160 | HER2-IN-21 | Inhibitor | / | Unkown |
| HY-156115 | EGFR/CDK2-IN-3 | Inhibitor | / | Unkown |
| HY-163632 | EGFR-IN-112 | Inhibitor | / | Unkown |
| HY-P0221A | PACAP (1-38), human, ovine, rat TFA | Inducer | / | Unkown |
| HY-183402 | FLLL12 | Inhibitor | / | Unkown |
| HY-32721S | Neratinib-d6 | Inhibitor | / | Unkown |
| HY-110045 | ZM-306416 hydrochloride | Inhibitor | / | Unkown |
| HY-153887 | HyT36(-Cl) | Control | / | Unkown |
| HY-183377 | DMBT | Inhibitor | / | Unkown |
| HY-169755 | Tyrphostin 63 | Inhibitor | / | Unkown |
| HY-180325 | DDC4002 | Inhibitor | / | Unkown |
| HY-169566 | EGFR-IN-146 | Inhibitor | / | Unkown |
| HY-10263 | BMS-554417 | Activator | / | Unkown |
| HY-183397 | Avitinib dihydrochloride | Inhibitor | / | Unkown |
| HY-158829A | SSOe26 sodium scrambled negative control | / | Unkown | |
| HY-178740 | GI261520A | Inhibitor | / | Unkown |
| HY-W740378 | 1,2,3,4-Tetrahydro Staurosporin | Inhibitor | / | Unkown |
| HY-118032 | Bozepinib | Inhibitor | / | Unkown |
| HY-164527 | Si306 | Inhibitor | / | Unkown |
| HY-135725 | D-69491 hydrochloride | Inhibitor | / | Unkown |
| HY-103443A | HKI-357 dimaleate | Inhibitor | / | Unkown |
| HY-180480 | NSC 104999 | Ligand | / | Unkown |
| HY-111300 | G3130 | Degrader | / | Unkown |
| HY-135727 | PF-6422899 | Inhibitor | / | Unkown |
| HY-180498 | NSC 57148 | Inhibitor | / | Unkown |
| HY-32718S | Pelitinib-d6 | / | Unkown | |
| HY-N14636 | Paeciloquinone B | Inhibitor | / | Unkown |
| HY-111072 | ADS103317 | / | Unkown | |
| HY-100742R | GNE-140 racemate (Standard) | Inhibitor | / | Unkown |
| HY-168305 | EGFR ligand-11 | / | Unkown | |
| HY-160068 | 2-2(t) aptamer sodium | Chemical | 99.28% | Unkown |
| HY-169948 | BML-265 | Inhibitor | / | Unkown |
| HY-50898S4 | Lapatinib-d7 | Inhibitor | / | Unkown |
| HY-183456 | Tyrphostin AG17 | Inhibitor | / | Unkown |
| HY-117523 | (Z)-RG-13022 | Inhibitor | / | Unkown |
| HY-19909A | NRC-2694-A | Inhibitor | / | Unkown |
| HY-W259575 | CDKi free base | Inhibitor | / | Unkown |
| HY-N14639 | Paeciloquinone E | Inhibitor | / | Unkown |
| HY-14674A | CP-724714 succinate | Inhibitor | / | Unkown |
| HY-137081 | AKOS024836912 | Inhibitor | / | Unkown |
| HY-50896S3 | Erlotinib-d8 | Inhibitor | / | Unkown |
| HY-15495B | (3S)-Tanzisertib hydrochloride | Inhibitor | / | Unkown |
| HY-N14638 | Paeciloquinone D | Inhibitor | / | Unkown |
| HY-N14637 | Paeciloquinone C | Inhibitor | / | Unkown |
| HY-16069S | Tucatinib-d6 | Inhibitor | / | Unkown |
| HY-163396 | EGFR-IN-107 | Inhibitor | / | Unkown |
| HY-111250 | SYR127063 | Inhibitor | / | Unkown |
| HY-10325R | CL-387785 (Standard) | Inhibitor | / | Unkown |
| HY-183400 | BIM-46174 | Inhibitor | / | Unkown |
| HY-159047 | EGFR ligand-10 | Degrader | / | Unkown |
| HY-158828A | SSO111 sodium scrambled negative control | / | Unkown | |
| HY-50896S2 | Erlotinib-d4 | Inhibitor | / | Unkown |
| HY-15769A | WHI-P180 hydrochloride | Inhibitor | / | Unkown |
| HY-116068 | DW532 | Inhibitor | / | Unkown |
| HY-114667 | Lavendustin C6 | Inhibitor | / | Unkown |
| HY-158829 | SSOe26 sodium | / | Unkown | |
| HY-156487 | CNBDA | Inhibitor | / | Unkown |
| HY-158828 | SSO111 sodium | / | Unkown | |
| HY-184315 | LDC8201 | Inhibitor | / | Unkown |
| HY-117252 | HS-72 | / | Unkown | |
| HY-169570 | EGFR-IN-149 | Inhibitor | / | Unkown |
| HY-N20729 | Eucommin A | Modulator | / | Unkown |
| HY-N14635 | Paeciloquinone A | Inhibitor | / | Unkown |
| HY-146262 | LDC0496 | Inhibitor | / | Unkown |
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-P9907A | Trastuzumab (anti-HER2) | Inhibitor | 99.838% | Unkown |
| HY-P9S0008 | Cetuximab (PBS) | Inhibitor | 99.33% | Unkown |
| HY-P99854 | Disitamab | Inhibitor | 98.73% | Unkown |
| HY-P9912A | Pertuzumab (anti-HER2) | Inhibitor | 99.10% | Unkown |
| HY-P990947 | Tilatamig | Inhibitor | 99.99% | Unkown |
| HY-P990957 | Ficerafusp alfa | 99.71% | Unkown | |
| HY-P99866 | Duligotuzumab | Inhibitor | 99.17% | Unkown |
| HY-P99684 | Laprituximab | Inhibitor | 99.74% | Unkown |
| HY-P990238 | Anti-Human/Rat HER2 (neu) Antibody (7.16.4) | Inhibitor | 95.00% | Unkown |
| HY-P991748 | Anti-Human/Mouse Amphiregulin Antibody (AR37) | Inhibitor | 99.544% | Unkown |
| HY-P9977A | Amivantamab (FUT8-KO) | Inhibitor | 98% | Unkown |
| HY-P990755 | Pamvatamig | 95.298% | Unkown | |
| HY-P99892 | Serclutamab | 99.97% | Unkown | |
| HY-P99948 | Etevritamab | 97.00% | Unkown | |
| HY-P99324 | Tomuzotuximab | Inhibitor | ≥99.0% | Unkown |
| HY-P99715 | Losatuxizumab | Inhibitor | 99.44% | Unkown |
| HY-P99406A | Petosemtamab (FUT8-KO) | Degrader | 99% | Unkown |
| HY-P99618 | Fidasimtamab | Inhibitor | 95.00% | Unkown |
| HY-P991662 | AMG-595 Antibody | 96.94% | Unkown | |
| HY-P99558 | Timigutuzumab | Inhibitor | 97.53% | Unkown |
| HY-P990978 | Caxmotabart | 96.56% | Unkown | |
| HY-P99888 | Pimurutamab | 99.42% | Unkown | |
| HY-P990909 | Calotatug | 98% | Unkown | |
| HY-P990962 | Vislarafusp alfa | 98.98% | Unkown | |
| HY-P991159 | Ruzaltatug | Inhibitor | 95.69% | Unkown |
| HY-P991780 | Anti-Mouse HER2 (domain I) Antibody (H2Mab-304) | Inhibitor | 97.589% | Unkown |
| HY-P990695 | Lunaxafusp (His Tag) | Inhibitor | / | Unkown |
| HY-P991505 | Anti-HER3 Antibody (Ab562) | Antagonist | 99.63% | Unkown |
| HY-P992137 | Turigrobart | Inhibitor | 99.9% | Unkown |
| HY-P991966 | Anti-Human/Mouse EGFR Antibody (7A7) | 99.45% | Unkown | |
| HY-P990972 | Azerutamig | / | Unkown | |
| HY-P991779 | Anti-Mouse/Human/Canine HER2 (domain III) Antibody (H2Mab-19) | Inhibitor | 99.05% | Unkown |
| HY-P992107 | Dulpatatug | Inhibitor | 99.09% | Unkown |
| HY-P992140 | Varzutamig | Inhibitor | / | Unkown |
| HY-P990755A | Pamvatamig (FUT8-KO) | Inhibitor | / | Unkown |
| HY-P991784 | Anti-Mouse/Human EGFR (domain III) Antibody (EMab-88) | Inhibitor | / | Unkown |
| HY-P991573 | Anti-EGFR Antibody (D2C7) | Inhibitor | / | Unkown |
| HY-P991980 | H2Mab-139 | Inhibitor | / | Unkown |
| HY-P991241 | Anti-ERBB3/HER3 (29Z6) | Inhibitor | / | Unkown |
| HY-P992171 | ADCT-701 Antibody | / | Unkown | |
| HY-P991783 | Anti-Mouse EGFR (domain I) Antibody (EMab-300) | Inhibitor | / | Unkown |
| HY-P991979 | Erbicin | Inhibitor | / | Unkown |
| HY-P991969 | LR004 | Inhibitor | / | Unkown |
| HY-P991236 | MHES0488A | Inhibitor | / | Unkown |
| HY-P991245 | Anti-ERBB3/HER3 (SGP1) | Inhibitor | / | Unkown |
| HY-P9968A | Nimotuzumab (powder) | Inhibitor | / | Unkown |
| HY-P990408 | Anti-ERBB1/EGFR/HER1 Antibody | Inhibitor | / | Unkown |
| HY-P991986 | Anti-Epiregulin Antibody | Inhibitor | / | Unkown |
| HY-P990248 | Anti-Mouse E-Cadherin/CD324 Antibody (DECMA-1) | Inhibitor | 98.53% | Unkown |
| HY-P991092A | IBI-334 (FUT8-KO) | Inhibitor | / | Unkown |
| HY-P991970 | REGN3124 | Inhibitor | / | Unkown |
| HY-P991239 | NM-02 | Inhibitor | / | Unkown |
| HY-P991968 | HTI-1511 Antibody | Inhibitor | / | Unkown |
| HY-P991967 | AVID100 Antibody | Inhibitor | / | Unkown |
| HY-P991243 | MP-RM-1 | Inhibitor | 96.29% | Unkown |
| HY-P992401 | M802 | Inhibitor | / | Unkown |
| HY-P99295A | Imgatuzumab (FUT8-KO) | Inhibitor | / | Unkown |
| HY-P991977 | BSI-001 | Inhibitor | / | Unkown |
| HY-P991234 | COVA208 | Degrader | / | Unkown |
| HY-P991985 | Anti-Her4 Antibody | Inhibitor | / | Unkown |